ImmunoCellular Signs Research Agreement With Antitope

ImmunoCellular Therapeutics, a biotechnology company, has signed a research agreement with UK-based biotechnology company Antitope for the humanization of IMUC’s monoclonal antibodies.

ImmunoCellular Therapeutics (IMUC) is advancing its monoclonal antibodies toward clinical trials, and humanizing the antibodies will provide for a safer therapeutic with less immunogenicity potential.

IMUC, through its recent acquisition of monoclonal antibody-related technology from Molecular Discoveries, has several novel monoclonal antibodies.

Manish Singh, president and CEO of IMUC, said: “We look forward to working with Antitope and believe that humanizing our antibodies is a key step in preparing these product candidates for human clinical trials, which we are targeting to initiate in 2010.”

Health Care Workers First Priority

If a flu pandemic swept the population of the United States, the government said Wednesday that essential health care workers would be the first to be immunized.

If a pandemic emerged, the Department of Health and Human Services released much anticipated details on who would get vaccinated.

“This guidance is the result of a deliberative democratic process,” HHS Secretary Mike Leavitt said in a statement. “This document represents the best of shared responsibility and decision-making.”

One million health care workers, such as emergency room staff and nurses, are at the top of the list, according to the plan. The next priority is military and “mission critical” personnel, public health workers and hospital and nursing home staff.

The plan reads, all of these people assume a “critical role in providing care for the sickest persons; highest risk of exposure and occupational infection.”

The plan did meet opposition.

Mike Osterholm, an infectious disease expert at the University of Minnesota’s Centers for Infectious Disease Research and Policy, said the plan did not do enough to protect critical workers.

Osterholm said, the plan protects people involved in making vaccines and drugs for flu, but it leaves out drugs such as insulin and antibiotics.

“It does nothing to help support the manufacturing and transportation system for moving these drugs from offshore to the United States,” said Osterholm, who advised the government on the guidelines.

Many public health experts agree some sort of influenza pandemic is inevitable, although no one can predict when it may hit, and how many it could affect.

H5N1 avian influenza is the main pandemic suspect. It has recently become entrenched in birds in Asia, Europe, the Middle East and possibly Africa.  Although it’s impossible to predict what strain of flu might cause it.

Since 2003, 385 people have been infected and 243 have died. Experts worry H5N1 could acquire the ability to spread easily from human to human. Some believe that would set off a pandemic that could kill hundreds of millions of people.

Manufacturing enough vaccine to protect everyone would take months. Experts put together a plan to determine who gets the first factory doses.

The HHS plan said 700,000 key health workers identified as critical, will be followed by 300,000 public health workers, 5.7 million inpatient and outpatient health care providers, and 1.6 million long-term care workers would be next to get the vaccine.

The plan said, “It should be noted that during the 1918 pandemic, more American soldiers died of illness than in combat during the First World War.”

The first designated groups also include emergency services, law enforcement, makers of pandemic vaccines and drugs, pregnant women and babies.

HHs said the plan would be changed depending on the characteristics of any real pandemic.

The last remaining group on the priority list is healthy adults.

There is a limited supply of antiviral drugs, but they can help protect people. To prevent the transmission of the flu, the U.S. plan would close schools and limit public gatherings.

At least 16 manufacturers in 10 countries are working on vaccines against H5N1.

On the Net:

Innolife Pharma Inc. Announces Record Setting Patient Bookings Scheduled

TORONTO, July 24 /PRNewswire-FirstCall/ — Innolife Pharma, Inc. (Other OTC:INNP.PK http://innp.pk/ – News) is pleased to announce that the booked patient appointments for the summer quarter (July, August and September) is up 140% over the previous quarter.

“Considering we are in the height of vacation season, we are very pleased with this significant increase in patient booking.” said Mr. Schiller, the President of Innolife Pharma Inc. “This only further serves as positive proof to the huge groundswell of chronic pain sufferers that are in dire need of this breakthrough non-narcotic treatment and our build out across North America of certified licensees will be in much demand.”

Today, one in five Americans suffer with chronic pain (~ 60 million adults) spending approximately $120 Billion a year and the aging baby boomers have reported in surveys more aches and pains than any previous generation.

   About Innolife Pharma Inc.   --------------------------  

Innolife Pharma Inc. (PINKSHEETS: INNP) is a small publicly traded specialty multi-discipline medical group focusing on licensing the Natural Pain Relief Center all-non-narcotic proprietary breakthrough in the treatment of chronic pain.

FORWARD-LOOKING STATEMENTS:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.

Innolife Pharma Inc.

CONTACT: Innolife Pharma Inc., T (416) 849-2275, F (416) 840-8431,Email: [email protected], http://www.innolifepharma.com/

GE Healthcare to Acquire Vital Signs, Inc., Expanding GE’s Monitoring, Anesthesia and Respiratory Care Offerings

GE Healthcare, a unit of General Electric Company (NYSE:GE), and Vital Signs, Inc. (NASDAQ:VITL) announced today that they have entered into a definitive merger agreement for GE to acquire Vital Signs. Under the terms of the agreement, shareholders of Vital Signs will receive $74.50 per share in cash for each Vital Signs share they own.

Vital Signs is a global provider of medical products applicable to a wide range of care areas such as anesthesia, respiratory, sleep therapy and emergency medicine. Vital Signs has a broad product offering of innovative single-patient use products which offer significant cost advantages and improved patient care features, including reducing the potential of transmitting infections from one patient to another. Vital Signs will become part of GE Healthcare’s Clinical Systems business, a world-class provider of advanced technologies for patient monitoring, anesthesia delivery and acute respiratory care. The strong strategic fit between the two businesses will offer substantial customer benefits through complementary product and service offerings.

“This acquisition is consistent with GE’s strategy to invest in high-technology, innovative businesses that deliver top-line growth, earnings expansion and expanded margins,” said John Dineen, President and CEO of GE Healthcare. “Vital Signs has consistently grown at double-digit rates while generating strong operating margins. Its products are a great complement to our existing anesthesia, monitoring and respiratory offerings.”

Commenting on the acquisition, Terry Wall, CEO of Vital Signs said, “This is a tremendous opportunity for us to further develop the Vital Signs business. We are proud of our innovative single patient use technologies and the contribution they have made to reduce patient mortality through limiting hospital acquired infections. By joining GE Healthcare, we see a huge opportunity to bring these products to many more hospitals and improve the care and health of patients worldwide.”

Omar Ishrak, President and CEO of GE Healthcare’s Clinical Systems business commented, “Vital Signs has an outstanding track record as a product innovator, with a well-earned reputation for supplying quality products. Vital Signs’ product offerings are highly complementary with our Clinical Systems business. We believe that combining the skills and knowledge of the two companies will create significant added value for our customers, bringing new technologies to healthcare professionals worldwide. Clinical Systems is a key area of growth for GE Healthcare and expanding our skill base and product offering in this area supports our vision of helping clinicians and nurses deliver the best possible care to their patients.”

The transaction, which is subject to Vital Signs’ shareholder and regulatory approvals, as well as other customary conditions, is expected to close in the 4th calendar quarter of 2008. The Boards of Directors of GE and Vital Signs have approved the transaction. The Board of Directors of Vital Signs has unanimously recommended the approval of the transaction by Vital Signs shareholders. The transaction values Vital Signs at approximately $860 million, net of Vital Signs cash and investments as of March 31, 2008. Shareholders holding approximately 37% of Vital Signs’ outstanding common stock have agreed, among other things, to vote their shares in favor of the proposed transaction.

ABOUT GE HEALTHCARE:

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.

GE Healthcare’s broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new “early health” model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.

ABOUT VITAL SIGNS INC.

Vital Signs, Inc. and its subsidiaries design, manufacture, and market primarily single-patient-use medical products for the anesthesia and respiratory/critical care markets. Vital Signs also provides devices and services for the diagnosis and treatment of obstructive sleep apnea. Vital Signs is ISO 13485 certified and has CE Mark approval for its products. In 2007, Forbes Magazine named Vital Signs, Inc. as one of the “200 Best Small Companies in America” based on financial criteria.

FORWARD LOOKING STATEMENTS

Any non-historical statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to several risks and uncertainties that could cause actual results to differ materially from such statements. The potential risks and uncertainties include, among others, the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, the inability to complete the merger due to the failure to obtain shareholder approval or the failure to satisfy other conditions to the completion of the merger, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the failure to receive other required regulatory approvals, general economic conditions, industry specific conditions and the possibility that Vital Signs may be adversely affected by other economic, business, and/or competitive factors, as well as other risks and uncertainties disclosed in Vital Signs’ 2007 Annual Report on Form 10-K filed with the Securities and Exchange Commission

IMPORTANT ADDITIONAL INFORMATION AND WHERE TO FIND IT:

In connection with the proposed merger, Vital Signs will file a proxy statement and other relevant materials with the Securities and Exchange Commission (the “SEC”). BEFORE MAKING ANY VOTING DECISION WITH RESPECT TO THE PROPOSED MERGER, INVESTORS AND SHAREHOLDERS ARE ADVISED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER AND THE PARTIES TO THE MERGER. Investors and shareholders may obtain a free copy of the proxy statement (when available) and other relevant documents filed with the SEC from the SEC’s website at www.sec.gov. Vital Signs’ shareholders and other interested parties will also be able to obtain, without charge, a copy of the proxy statement and other relevant documents (when available) by directing a request by mail to the company at 20 Campus Road, Totowa, New Jersey, 07512 or by telephone to 973-790-1330. Vital Signs and its directors and officers may be deemed to be participants in the solicitation of proxies from Vital Signs’ shareholders with respect to the merger. Information about Vital Signs’ directors and officers and their ownership of Vital Signs common stock is set forth in the Vital Signs proxy statements and Annual Reports on Form 10-K previously filed with the SEC, and will be set forth in the proxy statement relating to the proposed merger when it becomes available.

Aspect Medical Systems’ Letter to the Editor Regarding Anesthesia Awareness Study Published in New England Journal of Medicine

Aspect Medical Systems (NASDAQ: ASPM), the global market leader in brain monitoring technology, today announced that the Company’s letter to the editor regarding a study and editorial evaluating use of BIS(R) technology to reduce the risk of anesthesia awareness was published in the July 24th issue of the New England Journal of Medicine (NEJM). The NEJM also published letters from Dr. Paul Myles and co-investigators from the Australian B-Aware trial published in The Lancet in 2004, Dr. Lulong Bo and colleagues from Changhai Hospital in China, Dr. Diamanto Aretha and colleagues from University Hospital of Patras in Greece, and Dr. Tim M. Cook, from Royal United Hospital in Bath, United Kingdom. Responses from Dr. Michael Avidan and colleagues, authors of the NEJM study, and Dr. Beverly A. Orser, author of the NEJM editorial, were also published. A link to view this correspondence is available at www.aspectmedical.com.

“The awareness study recently published in the New England Journal of Medicine has prompted significant discussion throughout the global anesthesia community concerning the role of brain monitoring and the issues associated with too little as well as too much anesthesia,” said Scott Kelley, M.D., anesthesiologist and vice president and medical director of Aspect Medical Systems. “We are pleased that many leading anesthesia researchers and thought leaders have expressed the need to consider a variety of outcomes, including avoiding awareness, in managing a patient’s anesthesia care.”

A recent editorial published in the British Journal of Anaesthesia (BJA) following the 7th International Symposium on Memory and Awareness, provided a current assessment of clinical strategies to avoid awareness, including the role of depth of anesthesia monitoring. Notably, in commenting upon the NEJM study, the BJA editorial emphasized that the end-tidal anesthetic gas protocol used in the NEJM study is not reflective of current standard practice, but in fact is an alternate practice change that might be considered by clinicians. A link to this editorial is available at www.aspectmedical.com.

“The BJA editorial also highlights the emerging concerns related to anesthesia exposure and states that the NEJM study results support the need to ‘modify contemporary practice’ with one of the approaches shown to reduce risk of awareness,” said Dr. Kelley. “Avoiding awareness is just one of many goals that anesthesia professionals seek and, given the extensive clinical evidence and our experience in monitoring more than 27 million patients worldwide, we believe that use of brain monitoring to help guide anesthetic titration while maintaining a BIS value of less than 60 is a very effective way to individualize care, minimize awareness and improve patient outcomes.”

More information related to the NEJM publication can be found at Aspect’s Web site at www.aspectmedical.com, including Aspect’s commentary on the Avidan study and a comparison of the awareness trials led by Dr. Paul Myles and Dr. Michael Avidan.

Aspect includes in this press release links to its Web site. Aspect cautions you that the information on this Web site is not incorporated by reference into this press release and should not be considered to be a part of this press release.

About Aspect Medical Systems, Inc.

Aspect Medical Systems, Inc. (NASDAQ: ASPM) is a global market leader in brain monitoring technology. To date, the Company’s Bispectral Index (BIS) technology has been used to assess approximately 27 million patients and has been the subject of approximately 3,000 published articles and abstracts. BIS technology is installed in approximately 79 percent of hospitals listed in the July 2008 U.S. News and World Report ranking of America’s Best Hospitals and in approximately 75 percent of all U.S. operating rooms. In the last twelve months BIS technology was used in approximately 19 percent of all U.S. surgical procedures requiring general anesthesia or deep sedation. BIS technology is available in more than 160 countries. Aspect Medical Systems has OEM agreements with nine leading manufacturers of patient monitoring systems. For more information, please visit the Aspect Medical Systems Web site www.aspectmedical.com.

Cautionary Statement Concerning Forward-Looking Information

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may involve risks and uncertainties, including statements about the potential benefits of the Company’s brain monitoring technologies in helping anesthesia providers deliver anesthesia and in reducing the incidence of awareness and statements regarding the use and adoption of BIS monitoring technologies. There are a number of important factors that could cause actual results to differ materially from those indicated by these forward-looking statements. For example, future clinical trials and clinician use could demonstrate different and/or unfavorable results regarding the potential benefits of the Company’s brain monitoring product. The Company may also not be able to achieve widespread market acceptance of its BIS monitoring technology, or to compete with new products or alternative techniques that may be developed by others, including third-party anesthesia monitoring products approved by the FDA. Cases of awareness with recall during monitoring with the BIS system and significant product liability claims are among the factors that could limit market acceptance. The Company also faces competitive and regulatory risks relating to its ability to successfully develop and introduce enhancements and new products including the BIS VISTA monitor and products based upon its neuroscience technology. There are other factors that could cause the Company’s actual results to vary from its forward-looking statements, including without limitation those set forth under the heading “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 29, 2008 as filed with the Securities and Exchange Commission.

In addition, the statements in this press release represent the Company’s expectations and beliefs as of the date of this press release. The Company anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s expectations or beliefs as of any date subsequent to the date of this press release. Aspect, Bispectral Index and BIS are registered trademarks of Aspect Medical Systems, Inc. All other trademarks, service marks and company names are the property of their respective owners.

Annual Peach Festival Saturday

CURRITUCK COUNTY | The 19th annual Peach Festival will be from 9:30 a.m. to 5 p.m. Saturday, starting with a parade, and 10 a.m. to 5 p.m. Sunday on the grounds of the Ruritan Community Park on Brumley Road in Knotts Island.

There will be activities for children, including train rides, moonwalk, super slide, bungee run, obstacle course and pedestal jousting. There will be vendors with wildlife carvings, decoys, home crafts, garden accessories and clothing, and displays involving antique cars, fire departments, Back Bay Mining and Mackay Island Wildlife Refuge.

The cost is $5. Children 12 and younger are admitted free when with an adult. For details , visit http://knottsislandonline.com/ ruritan/club.festivals/peachfest/peach_fest.htm.

Currituck County

Two earn status of eagle scout

Boy Scout Troop 826 members Daniel Copans and Aaron Moura of the National Capital Area completed Leadership Service Projects needed to obtain Eagle Scout status.

Daniel’s project was to help Lighthouse Keeper Luis Garcia prepare and repaint the storehouse of the Currituck Beach Light Station, which was completed with the help of nine other scouts and two troop leaders.

Aaron consulted with Whalehead Club Maintenance Supervisor Gary Shuk and wrote a project plan to help the Whalehead Preservation Trust maintenance staff rebuild picnic tables with more durable material and build containers for recyclable items.

Both crews spent an entire day on their projects.

Dare County

Lunch and learn workshop IS friday

A workshop, Advances in the Treatment of Kidney Cancer, will be from noon to 1 p.m. Friday at the Cancer Resource Center in the medical building behind The Outer Banks Hospital.

Dr. Kim Rathmell from the University of North Carolina at Chapel Hill’s Lineberger Comprehensive Cancer Center will present the workshop.

A complimentary light lunch will be served. Seating is limited, and registration is required.

Call (252) 475-5079 or e-mail [email protected].

Church group to hold fish fry

The Methodist Men of Mount Olivet United Methodist Church will hold a fish fry from 4 to 8 p.m. Saturday at the church in downtown Manteo.

Plates will include fresh local fried fish, coleslaw, baked beans, hush puppies and iced tea for $8. Homemade desserts will be available for purchase.

Proceeds will be used to finance community service projects.

For more information or to buy tickets in advance, call the church office at (252) 473-2089, ext. 21.

lifeguards pLace in competition

Nags Head Ocean Rescue recently placed first in the South Atlantic Lifesaving Association regional championships for the small agency division, 50 guards on staff or less. The group had 10 competitors.

John Kenny took first in five events, including 50-54 Rescue Board, 50-54 Run-Swim-Run, 50-54 Men-Surf Ski, 50-54 International Ironman, and 50-54 Men-Beach Flags. Sasha Zevenhuizen took first in the Open International Ironwoman, and Terese Chisholm took first in the Open Women-Run-Swim-Run.

Corolla Ocean Rescue came in second with 11 competitors, seven taking first place in various events including Sylvia Wolff, Elle Moore, Mike Hudson, Steve Hilik, Shaun Buen, Brian Burkhardt and Ricky DeVennish.

Pasquotank County

wesley to host open house

Observing National Hospitality House Week, Wesley Hospitality House will hold an open house, “Homes that Help and Heal,” from 11 a.m. to 5 p.m. Friday.

The week’s activities will recognize the contributions of local volunteers, organizations, individuals and businesses to its success.

Hospitality houses help families whose loved ones are receiving treatment for serious illness or injuries at hospitals far from their home communities.

Since opening in 2000, the Wesley Hospitality House has served more than 5,000 guests from various counties and different states.

The event will include tours, hot dogs, chips and soda with entertainment.

Chamber auction set for Saturday

The 10th Elizabeth City Area Chamber of Commerce will present “Carnival in Rio” beginning at 7 p.m. at The Pines at Elizabeth City.

A silent auction will begin at 7 p.m., followed by live auction at 9. There will be Signature Rio cocktails, food and entertainment. Cost is $35.

The event is sponsored by Elizabeth City Brick Co.

regional

Blue crab festival set for saturday

The South Norfolk Ruritan Club will hold a Blue Crab Festival from 1 to 4 p.m. Saturday at the Khedive Shrine Center, 645 Woodlake Drive in Chesapeake.

The menu includes all-you-can-eat steamed crabs, barbecue, coleslaw, hush puppies and beverages. Entertainment will be provided by The River Boys.

Tickets cost $25 in advance, $30 at the gate. Tickets are on sale at any branch of Bank of Hampton Roads and any Ruritan club member.

For more information, call (757) 362-7975 or (757) 477-0554.

meetings + events

DARE COUNTY

Outdoor movie 8 p.m. Saturday, Roanoke Island Festival Park Outdoor Pavilion (film theater in case of rain). “The Cameraman” will be shown. Free.

PASQUOTANK COUNTY

Blood drive 11 a.m. to 4 p.m. today, Golden Corral (blood drive is on the bus).

PERQUIMANS COUNTY

Pancake breakfast 7 to 10 a.m. Saturday, Bethel Ruritan Club, 392 Snug Harbor Road. $5.

Benefit singing 7 p.m. Saturday, New Hope Assembly of God, 113 Deep Creek Road, Durant’s Neck, local talent, silent auction and bake sale to benefit building fund.

Beverlie Gregory, (252) 441-1620,

[email protected]

Karen Santos, (252) 338-2590,

[email protected]

(c) 2008 Virginian – Pilot. Provided by ProQuest Information and Learning. All rights Reserved.

New Medical College Expected to Make Deep Impact

By David Lester

Maria Cadwell thought about attending medical school in Colorado, where she could pursue her chosen vocation of medicine and her avocation of skiing.

But she made a sharp turnaround when the chance to attend the new Pacific Northwest University of Health Sciences in Yakima became available.

Cadwell said she’s glad she did. She’s now member of the first class of future physicians to attend the new university.

“I am real excited to be so close to White Pass and Mount Adams and outdoor recreational activities,” said the 26-year-old graduate of the University of California at San Luis Obispo. “I’m from the Tri-Cities, and Yakima is an hour closer to the ski area.”

Cadwell is among the first 75 students to attend $20 million, 45,000-square-foot College of Osteopathic Medicine, which will be dedicated this afternoon in a ceremony expected to draw up to 500 people.

What began four years ago as an idea by a few local osteopathic physicians picked up steam when community and business leaders dropped their skepticism and came up with the seed money needed to get the plan through initial fundraising and accreditation hurdles.

By the time Cadwell graduates in 2012, the student body is expected to have as many as 400, according to current plans, with 200 on campus. The other 200, the third- and fourth-year students, will be undergoing clinical rotations at hospitals and clinics here and elsewhere in the region.

All of these students during their stays here will be buying or renting homes, purchasing groceries and clothing, attending local events and, in Cadwell’s case, skiing.

A 2006 economic impact study commissioned by the fledgling university estimated an annual payroll of nearly $6 million by 2012. Faculty and staff will spend more than $22 million on housing during that four-year period, and another $3.4 million on taxable household purchases.

The estimates are based solely on the first building on the campus, the College of Osteopathic Medicine that will be the subject of today’s dedication ceremony.

Organizers hope other colleges will be added for specialties, such as occupational and physical therapy and public health administration.

“In four years, there will be additional schools. I’m certain of that,” forecast Tim Morris, the university’s chief operating officer. “Part of that has been the board’s direction.”

Ultimately, the 42-acre campus could include nine additional buildings erected to train students in other health-care careers.

That has been the experience in rural Kirksville, Mo., home to the nation’s first osteopathic medical school.

Although much smaller than Yakima with a population of 17,000, Kirksville is home to about as many on-campus students as Pacific Northwest expects to have, about 200 to 300.

Their presence has had a major impact on the rural economy of northern Missouri, according to Alisa Kigar, executive director the past seven years for the Kirksville Area Chamber of Commerce.

Kigar could not provide figures on the economic impact, but said it is significant.

“These people … are buying homes, cars, buying food, giving back to the community,” she said. “They are paying for entertainment.”

Not just economics

Unlike Cadwell, who opted to rent an apartment with two other students, Dr. Raul Garcia-Rodriguez bought a home on Scenic Drive.

Garcia, Pacific Northwest’s assistant dean of postdoctoral affairs, said he expects the university will have a major impact on real estate with upwards of 300 families, including faculty and students, residing in Yakima.

Garcia, who also is an emergency room physician at Yakima Regional Medical and Cardiac Center, said he anticipates other economic spinoff benefits as well.

“Because we are bringing people here with different wants and likes, there will be a need for Mediterranean restaurants, more sushi bars and Chinese food and other kinds of cuisine,” said Garcia, who is of Cuban descent and grew up in Miami.

Garcia, 37, also foresees more entertainment opportunities and cultural events, a tourism boom and a more diverse population.

“You place 400 new students with families in this city and all the different cultures and habits, Yakima will be more of a melting pot than it is now,” he said.

Other benefits that don’t express themselves in immediate economic terms will aid the community and the region.

One is an improvement in the overall health of community residents.

Following its mission to provide quality care to communities of the Northwest, particularly underserved populations, the university is expected to increase the number of physicians in the area, historically a chronic problem for Central Washington.

It has certainly been the case in rural Missouri.

Kigar said the area is three hours from a major airport and has only one Wal-Mart in a 12-county area, but has a number of medical specialties available to Kirksville-area residents.

Kigar said the area has a low physician-to-patient ratio.

“They stick around. They love the rural lifestyle,” she said of Kirksville physicians.

Today’s Dedication

Mike Gregoire, husband of Washington Gov. Chris Gregoire, and a supporting cast in the hundreds are expected to be on hand for today’s dedication of the newest medical school in the country.

A ceremony to commemorate the $19.7 million Pacific Northwest University of Health Sciences is scheduled for 2 p.m. in front of the school at 111 University Parkway (formerly South 33rd Street) in Terrace Heights.

University officials say they expect more than 500 people from the Yakima community and as far away as Pennsylvania on hand.

Residents planning to attend are advised to arrive early because parking will be at a premium. Parking will be available at the Iron Horse Development building, at Terrace Heights Drive and University Parkway; the neighboring Yakima Valley Credit Union and along the street.

Dr. Stanley Flemming, university president, will preside over the ceremony.

Tours of the 45,000-square-foot building will follow.

Classes begin Aug. 4.

David Lester

Yakima Herald-Republic

(c) 2008 Yakima Herald-Republic. Provided by ProQuest Information and Learning. All rights Reserved.

Women Named to New Positions at Owensboro Medical Health System

By Messenger-Inquirer, Owensboro, Ky.

Jul. 24–Sally Harris has been named director of women’s services for Owensboro Medical Health System. Harris will oversee labor and delivery, obstetrics, postpartum, pediatrics, the nursery, and the women’s surgical care unit, the nursing unit she most recently managed. Harris has practiced nursing for more than 16 years has also held positions as pulmonary rehabilitation coordinator, a school health nurse and staff nurse. She earned a nursing degree from Kentucky Wesleyan College and a bachelor of general studies with a health emphasis from Western Kentucky University, where she is also completing her bachelor’s degree in nursing and master’s degree in organizational communication.

— Deanna Payne has been named manager for the hospital’s women’s surgical unit. She has more than 17 years experience as a nurse and was most recently director for the OMHS Wound Healing Center. She is a graduate of Kentucky Wesleyan College and holds a bachelor’s degree in nursing. She has also served as a staff nurse in outpatient surgery and endoscopy as a health promotion specialist at the OMHS HealthPark.

— Pam Vanover has been named manager of Sterile Processing. Vanover is a registered nurse and holds more than 20 years experience in the operating room environment. She has held positions as a staff nurse, serving in multiple roles, and also as a clinical supervisor. She is a certified operating room nurse and holds a nursing degree from Kentucky Wesleyan College.

— Debra Poole has been named manager of inpatient behavioral health services. She has over 20 years experience in behavioral health nursing and management. She is a graduate of Murray State University and holds a bachelor’s degree in nursing.

—–

To see more of the Messenger-Inquirer, or to subscribe to the newspaper, go to http://www.messenger-inquirer.com.

Copyright (c) 2008, Messenger-Inquirer, Owensboro, Ky.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

The Connecticut Hospice, Inc. Announces the Arrival of Six Nurse Scholars From The Henrietta Szold-Hadassah-Hebrew University School of Nursing

To: MEDICAL EDITORS

Contact: Lauren Brown of The Connecticut Hospice, +1-203-315- 7556, [email protected]

BRANFORD, Conn., July 24 /PRNewswire-USNewswire/ — The Connecticut Hospice, Inc., birthplace of Hospice in America, is proud to announce the arrival of six Nurse Scholars from The Henrietta Szold-Hadassah-Hebrew University School of Nursing, Jerusalem Israel, in conjunction with New York University College of Nursing.

Lauren Brown, MSN, Co-Director of Education, together with Marianne Treantafilos, APRN, architect of the Norma F. Pfriem International Fellowship in Hospice and Palliative Nursing, stated that, this is the second time in as many years that the nursing scholars have arrived from Israel. The Directors noted that part of their work will require the nurse scholars to clinically round with the interdisciplinary team at 6:30 every morning.

The Connecticut Hospice, Inc. will provide these post-graduate nurses with the opportunity to assess the multi-dimensional needs of new or continuing patients and families receiving care in the Hospice Hospital of Palliative Care setting and the Hospice Homecare setting. The nurse scholars will observe communication modalities used by the Hospice nurses, APRNs, physicians and other staff with patients and families to help the patients/families reach their ultimate goals.

Nurse scholars will learn the key elements of assessment of patients with irreversible disease, including physical symptoms, as well as psychosocial and spiritual aspects of care. The graduate nurses and the Connecticut Hospice nurse preceptors will have the opportunity to reflect on professional and personal challenges of caring for patients at the end of life.

SOURCE The Connecticut Hospice

(c) 2008 U.S. Newswire. Provided by ProQuest Information and Learning. All rights Reserved.

HPV Vaccine Could Bring Jobs: Chamber President: ‘This is Very Exciting News’

By Keith Lawrence, Messenger-Inquirer, Owensboro, Ky.

Jul. 24–Owensboro’s Kentucky BioProcessing LLC has signed a deal that could have a huge impact on the region’s economy — if a new human papillomavirus vaccine is successful.

Louisville-based Advanced Cancer Therapeutics has signed a deal with the University of Louisville’s James Graham Brown Cancer Center to license its technology for a second-generation HPV vaccine.

And a second deal with Kentucky BioProcessing will allow ACT to use the Owensboro company’s patented GENEWARE technology to grow the vaccine inside tobacco plants and to use the Owensboro facilities for commercial production if the new product is approved for the U.S. and world markets.

If that happens, “a very, very significant capital investment would be needed” to Kentucky BioProcessing’s facilities, Hugh Haydon, KBP chairman, said Wednesday. “But the business would be there to support it.”

“This is very exciting news for KPB and the community as a whole,” said Jody Wassmer, president of the Greater Owensboro Chamber of Commerce. “It’s real proof that Owensboro-Daviess County can be a real player and job producer in the pharmaceutical world.”

HPV is a leading cause of cervical, anal and vaginal cancer, and about 20 million people are infected with the sexually transmitted disease, according to the Centers for Disease Control and Prevention.

The agency says “at least 80 percent of women will have acquired a genital HPV infection by age 50, with about 6.2 million Americans contracting a new genital HPV infection each year.”

Randall B. Riggs, ACT’s president and CEO, said 500,000 new cases of cervical cancer are reported each year. And, he said, scientists are also beginning to implicate HPV in various head, neck and lung cancers in both men and women.

“That effectively doubles the market for the vaccine, once you add men,” Haydon said.

The Food and Drug Administration estimates that it takes an average of eight years of testing to win approval for a new drug.

Riggs said it could take less time for the new vaccine because of the work already done on Gardasil, a vaccine against certain types of HPV that was created by Dr. Albert Bennet Jenson and Dr. Shin-je Ghim at the University of Louisville in 2006.

Gardasil costs about $350 for a three-dose series.

But 80 percent of the cervical cancer cases are in developing countries, Riggs said.

The new vaccine, he said, may provide broader immune protection against a greater number of the more than 200 strains of HPV at a lower cost than current vaccines.

Growing the vaccine in plants can help cut costs, Riggs said.

“Our goal is to provide a cost-effective vaccine,” he said. “We hope to open up markets in China and India.”

Those two countries have a combined population of 2.6 billion.

Haydon said some countries have a shorter window for testing new drugs than the United States. It’s possible that ACT could begin production in Owensboro for the world market before it receives FDA approval to sell the product in this country, he said.

KBP, which describes itself as “a world leader in the expression, extraction, purification and commercial scale production of proteins and other products from plants,” operates a 30,000-square-foot biomanufacturing facility with an adjacent 22,000-square-foot greenhouse at 3700 Airpark Drive.

It’s not large enough for the type of production that would be required for worldwide sales of a vaccine. “It wouldn’t happen all at once,” Haydon said. “We would have time to ramp up for production if we get there. And we hope we get there.”

ACT isn’t the company’s only customer.

Last year, two start-up companies — Mapp Biopharmaceuticals and Intrucept Biomedicine — established a local presence at KBP.

Haydon said earlier this summer that KBP is working with a dozen biotech companies on products at its bioprocessing facility. “And we’re in discussions with upwards of 20 others,” he said.

On Wednesday, Haydon said he expects at least one and maybe two more announcements this summer.

Pharmaceutical production, he said, isn’t subject to boom-and-bust cycles. The demand for medicine never slacks, Haydon said.

The intellectual property to develop the HPV vaccine, licensed to ACT through University of Louisville’s Office of Technology Transfer, is based on research by Jenson, Kenneth Palmer and their colleagues.

Palmer conducts research at the Owensboro Cancer Research Program, a joint venture between Owensboro Medical Health System and U of L at the Mitchell Memorial Cancer Center.

“We hope that the technology we are using to manufacture this vaccine will yield a product at a cost that will facilitate its use in resource-poor areas of the world where vaccines against HPV are most needed,” he said in a news release.

“Our research to date indicates that the technology we are using to produce the vaccine protein in plants will be very cost-effective.”

—–

To see more of the Messenger-Inquirer, or to subscribe to the newspaper, go to http://www.messenger-inquirer.com.

Copyright (c) 2008, Messenger-Inquirer, Owensboro, Ky.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Cornerstone Pharmaceuticals Announces Approval to Conduct Phase I/II Clinical Trial of CPI-613 in Cancer Patients By US FDA

Cornerstone Pharmaceuticals, Inc., a privately held pharmaceutical company, announced today that it has received clearance from the US Food and Drug Administration (FDA) to begin a Phase I/II clinical trial evaluating the safety and early efficacy of its first-in-class Altered Energy Metabolism-Directed (AEMD) compound, CPI-613, in a variety of cancer types.

CPI-613 targets distinctive changes in the energy generating processes associated with the vast majority of solid tumor types, according to preclinical studies. CPI-613 has shown possible utility in multiple preclinical studies including studies conducted using human tumor biopsies from patients bearing lung, colon, pancreatic and breast tumors as well as cancer cell lines resistant to traditional chemotherapeutics.

The approved clinical trial will be open to patients with a variety of tumor types who have failed previous therapies. It will be conducted at a limited number of clinical trial sites in North America.

CPI-613 represents a subclass of compounds from Cornerstone’s AEMD platform which the company has named “Thioctans,” and which it believes kill cancer cells by an entirely new and highly selective mechanism.

“We are optimistic that this approval will mark the next important step towards establishing these drugs as a safer, more effective way to treat a wide variety of cancer types, which could make a significant difference in the lives of cancer patients everywhere,” said Robert Shorr, Ph.D. D.I.C., Chief Executive Officer of Cornerstone.

Recent studies in molecular biology have focused on the significant genetic variances between different types of cancers. However, it has long been recognized that metabolic energy processes in the majority of cancer cells are similar to each other, but quite distinct from that of normal cells. This observation, first made by Nobel Laureate Otto Heinrich Warburg in 1924 (the “Warburg Effect”), forms the basis for recent significant advances in cancer imaging by positron emission tomography (PET). This altered energy metabolism, common to many types of cancer but not normal cells, is the target of Cornerstone’s unique chemotherapeutic intervention.

CPI-613 has been shown to be well tolerated at doses that significantly exceed effective anti-tumor doses in several different animal models of human tumors. These findings, among others, have led to the decision to evaluate CPI-613 in this clinical trial.

“Considering the proposed novel mechanism of action, the broad spectrum of activity among a variety of tumor types, the observed low toxicity profile, and potential synergy with existing approved cancer therapies – all of which have been demonstrated in our preclinical work – I believe CPI-613 has the potential to represent a significant advancement in chemotherapeutic options for the treatment and management of a broad variety of cancers,” said Richard Lutes, M.D., Cornerstone’s Chief Medical Officer.

The CPI-613 trial is designed as an open label, dose-escalation study to evaluate safety, tolerability, maximum tolerated dose, efficacy, and pharmacokinetics of CPI-613 in multiple types of cancer patients.

Cornerstone has been granted Orphan Drug Designation by the US FDA for the use of CPI-613 in the treatment of pancreatic cancer.

Cornerstone’s AEMD technology platform was established on cancer metabolism research performed in the laboratories of Paul M. Bingham, Ph.D. and Zuzana Zachar, Ph.D., at the State University of New York at Stony Brook, Stony Brook, NY.

Cancer is the second leading cause of death in the US. Excluding basal and squamous cell skin cancers, the American Cancer society predicts that over 1.4 million new cases of cancer and nearly 600,000 cancer related deaths will occur in the US in 2008.

About Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals, Inc., is a privately held pharmaceutical company singularly focused on the discovery and development of innovative cancer therapies that exploit the metabolic pathways that are common to different cancer types but different from normal cells and tissues. This unique approach, i.e. understanding and addressing what is similar to multiple cancer types rather than the differences between each, offers a significant opportunity to make a profound impact on the clinical treatment of a variety of cancers.

Cornerstone is currently developing two distinct technology platforms that show strong specificity for cancer cells of multiple types:

— Altered Energy Metabolism-Directed (AEMD) small molecule drugs; and

— Emulsiphan, a cancer-selective nanotechnology-based delivery system

Cornerstone has offices and laboratory facilities in both Stony Brook, NY and Cranbury, NJ. For more information, please go to http://www.cornerstonepharma.com

Momenta Pharmaceuticals Appoints Bruce A. Leicher As General Counsel

CAMBRIDGE, Mass., July 24, 2008 (PRIME NEWSWIRE) — Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Bruce A. Leicher, J.D. has been appointed as the Company’s Senior Vice President and General Counsel.

Craig A. Wheeler, CEO of Momenta, commented, “Bruce brings nearly 20 years of legal experience in the biotechnology industry to Momenta, and we are very pleased to have him join our executive team. In particular, his expertise with the management of a broad range of complex biotechnology legal matters, including intellectual property litigation, adds invaluable expertise to our organization as we advance our pipeline of generic and novel compounds.”

Prior to joining Momenta, Mr. Leicher was Senior Vice President and General Counsel at Altus Pharmaceuticals. He previously served as General Counsel at Antigenics Inc., as Vice President and Chief Pharmaceutical Counsel for Millennium Pharmaceuticals, Inc. and as Vice President, Legal for Genetics Institute, Inc. Mr. Leicher received his J.D. from Georgetown University Law Center and his B.A. from the University of Rochester.

About Momenta

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs. The Company’s most advanced product candidate, M-Enoxaparin, is designed to be a technology-enabled generic version of Lovenox(r). Momenta’s first novel drug candidate is M118, a rationally engineered anticoagulant specifically designed for acute coronary syndromes. Within the Company’s discovery program, it is seeking to discover and develop novel therapeutics by applying its technology to better understand sugars’ functions in biological processes, with an initial focus in oncology. Momenta was founded in 2001 based on technology initially developed at Massachusetts Institute of Technology and is headquartered in Cambridge, MA.

To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.

This news release was distributed by PrimeNewswire, www.primenewswire.com

 CONTACT:  Momenta Pharmaceuticals, Inc.           Beverly Holley           617-395-5189            Yates Public Relations           Media:           Barbara Yates            781-258-6153 

Eclipsys Hits Strong Pharmacy Benchmarks in 2008

Eclipsys Corporation(R), (NASDAQ:ECLP), The Outcomes Company(R), today announced it has hit strong pharmacy benchmarks in the first six months of 2008, with the company meeting its target to double the number of sites live on its Sunrise Pharmacy(TM) integrated pharmacy information system. Introduced to the marketplace two years ago, the solution is now used by more than 1,000 trained pharmacists and technicians to provide the highest levels of medication management and clinical outcomes.

A key factor to the market appeal of the pharmacy solution lies in its native integration with the Eclipsys’ market-leading computerized physician order entry (CPOE) system, Sunrise Acute Care(TM). Working in concert via a single database, the two systems enable integrated handoffs between clinicians and pharmacists to make for fewer errors and accelerated time to treatment. In fact, more than half of the Eclipsys clients live on Sunrise Pharmacy boast a physician adoption rate of greater than 75 percent for Eclipsys’ CPOE system.

“Having our CPOE and pharmacy system on the same platform as order entry and electronic medication administration record has helped our organization to make the medication process safer and more efficient,” said Laura Mark, director of Pharmacy, West Penn Allegheny Health System. “Automating the medication management process through the use of Eclipsys solutions supports our commitment to achieving the best possible patient care outcomes.”

“Eclipsys’ recent success with activating a large volume of Sunrise Pharmacy sites reflects the benefits of our solution’s superior integration,” said Jay Deady, executive vice president, Client Solutions, Eclipsys Corporation. “As we continue to demonstrate our ability to address client challenges and enable vastly improved safety in medication administration, we anticipate documenting additional client outcomes and achieving client satisfaction levels well above the industry average.”

Sunrise Pharmacy, a key component of Eclipsys’ Sunrise Medication Management(TM) solution, enables pharmacists to quickly and easily enter or review and verify physician orders. The single application screen view helps the pharmacist to effectively manage multiple tasks and save time. Shared real-time information enhances the pharmacist’s ability to deliver the patient’s medications with greater accuracy, and in less time, even when a physician goes back and modifies or cancels an order placed earlier. Advanced clinical decision support for checking medication contraindications helps to reduce adverse drug events.

About Sunrise Medication Management

Sunrise Medication Management is Eclipsys’ solution suite that delivers the essential components of medication management automation on a single platform and shared database. In combination the offering helps to prevent points of failure where information could be mis-transcribed, mis-communicated or simply missed. With Sunrise Medication Management, each individual in the medication management process has a complete and up-to-the-minute view of the patient and the other caregivers’ decisions and actions. For physicians, user-friendly CPOE and customizable order sets that support complex treatments, such as chemotherapy, helps facilitate timely and accurate orders. In the pharmacy, automated order verification reduces delays. Pharmacists can quickly select the right drug, dose, route and cost in keeping with formulary requirements. Before administering medications, nurses use bar code scanning to check the “five rights,” triggering the automatic update of the electronic medical record, simultaneously saving time and improving accuracy.

About West Penn Allegheny Health System

Comprised of two tertiary and four community hospitals, WPAHS includes Allegheny General Hospital and The Western Pennsylvania Hospital, both in Pittsburgh; Alle-Kiski Medical Center in Natrona Heights; Canonsburg General Hospital in Canonsburg; The Western Pennsylvania Hospital – Forbes Regional Campus in Monroeville; and AGH-Suburban Campus in Bellevue. Offering a comprehensive range of medical and surgical services, the hospitals serve Pittsburgh and the surrounding five-state area, house more than 2,000 beds and employ more than 13,000 people. Together, the WPAHS hospitals admit more than 80,000 patients each year, log in excess of 173,000 emergency visits and deliver nearly 6,000 newborns. Combined, the hospitals are among the leaders in percentages of total surgeries, cardiac surgeries, neurosurgeries and cardiac catheterization procedures performed throughout the region. Allegheny General Hospital serves as the clinical campus for the Drexel University College of Medicine in Philadelphia, and The Western Pennsylvania Hospital serves as the clinical campus for Temple University School of Medicine in Philadelphia. For details, see www.wpahs.org.

About Eclipsys

Eclipsys is a leading provider of advanced integrated clinical, revenue cycle and access management software, clinical content and professional services that help healthcare organizations improve clinical, financial, operational and client-satisfaction outcomes. For more information, see www.eclipsys.com or email [email protected].

Statements in this news release concerning the timing of features and benefits provided by Eclipsys software and implementation services are forward-looking statements and actual results may differ from those projected due to a variety of risks and uncertainties. Implementation and customization of Eclipsys software is complex and time-consuming. Results depend upon a variety of factors and can vary by client. Each client’s circumstances are unique and may include unforeseen issues that make it more difficult than anticipated to implement or derive benefit from software or services. The success and timeliness of the company’s services will depend at least in part upon client involvement, which can be difficult to control. Eclipsys is required to meet specified performance standards, and the contract can be terminated or its scope reduced under certain circumstances. More information about company risks is available in recent Form 10-Q and 10-K filings made by Eclipsys from time to time with the Securities and Exchange Commission. Special attention is directed to the portions of those documents entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Eclipsys Corporation and The Outcomes Company are registered trademarks of Eclipsys Corporation. Sunrise Acute Care, Sunrise Pharmacy and Sunrise Medication Management are trademarks of Eclipsys Corporation. Other product and company names in this news release are trademarks and/or registered trademarks of their respective companies.

Delcath Expands Phase III Trial for Metastatic Melanoma to Florida

Delcath Systems, Inc. (NASDAQ: DCTH) announced today that Moffitt Cancer Center (“Moffitt”), a National Cancer Institute Comprehensive Cancer Center, has joined Delcath’s Phase III clinical trial for the treatment of inoperable metastatic melanoma in the liver using the Company’s Percutaneous Hepatic Perfusion (PHP) System for the isolated, high dose delivery of the anti-cancer agent melphalan. Moffitt is the seventh center in this multi-center trial using the Delcath System.

Delcath and Moffitt have entered into a clinical research agreement to conduct the Phase III National Cancer Institute (NCI) led study. Jonathan S. Zager, MD, Assistant Professor of Surgery in the Department of Oncologic Sciences and a member of the Division of Cutaneous Oncology at Moffitt will serve as the Principal Investigator of the study. On joining this study, Dr. Zager commented, “This is a tremendous opportunity for Moffitt and our patients to be able to enroll in this trial. Metastatic melanoma is a devastating disease, providing limited treatment options and resistant against most therapies. This trial provides hope and promise to patients suffering from this disease and we look forward to being able to assist in the enrollment process and bettering our patients’ prognoses.”

Commenting on Moffitt joining this trial, Richard L. Taney, President and CEO of Delcath, stated, “Our expansion of this trial continues and we are very excited to be able to enroll patients at Moffitt under the leadership of Dr. Zager, who brings broad experience in melanoma and clinical research to this study. By working with leading melanoma physicians and centers, such as Dr. Zager and Moffitt, we are increasing the availability of this treatment option to more geographic regions and patients. We will continue our efforts to broaden the reach of this trial through the addition of recognized cancer centers, make this treatment option available to as many patients as possible, and to reach our goal of completing trial enrollment in 2009.”

The Phase III Study

The Phase III study is designed to test Delcath’s proprietary PHP System for the regional delivery of melphalan to the liver to treat patients with metastatic ocular and cutaneous melanoma who have unresectable tumors in the liver. The Delcath System is designed to deliver significantly higher doses of anti-cancer drugs to a patient’s liver while preventing entry of the drugs to the rest of the patient’s circulation. This isolation limits toxicities that result from systemic chemotherapy treatments.

Patients in the Phase III trial initially are randomized into one of two treatment arms, including immediate treatment with melphalan via the Delcath System or treatment with best alternative care. The study is designed to evaluate the duration of tumor response in each of the two study arms. Following guidelines established by U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA), when disease progresses in patients enrolled in the best alternative care arm of the trial, they are permitted to “cross over” and receive treatment with the Delcath System. The Phase III study, which recently exceeded 33% enrollment, is expected to be completed in 2009, leading to an application to the US Food and Drug Administration (FDA) for commercial approval of the PHP System.

About H. Lee Moffitt Cancer Center & Research Institute

Located in Tampa, Florida, Moffitt Cancer Center is the only Florida-based cancer center with the NCI designation as a Comprehensive Cancer Center for its excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 15 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country’s leading cancer centers, and is listed in U.S. News & World Report as one of “America’s Best Hospitals” for cancer, as well as for ear, nose and throat. Moffitt’s sole mission is to contribute to the prevention and cure of cancer.

About Delcath Systems, Inc.

Delcath Systems is a developmental stage company testing its percutaneous perfusion technology for the isolated delivery of high doses of therapeutic and chemotherapeutic agents. The Delcath System is currently being tested with the drug melphalan in Phase III and Phase II clinical trials. The Company’s intellectual property portfolio currently consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company’s website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

 Company Contact: Delcath Systems, Inc. Richard Taney (212) 489-2100 www.delcath.com  Investor Relations Contact: Strategic Growth International, Inc. Richard E. Cooper (212) 838-1444 Email Contact

SOURCE: Delcath Systems, Inc.

Medivisor Inc. Announces New Sales and Marketing Agreement for Mucotrol(TM) With Cura Pharmaceutical Co Inc.

Medivisor Inc. (PINKSHEETS: MVSR) today announced that it has signed a new sales and marketing agreement with Cura Pharmaceutical for the marketing of Mucotrol(TM) in the United States. The groundbreaking drug Mucotrol(TM) is an oral gel wafer that received 510-K approval as a device from the FDA in late November 2004, as a treatment for mouth sores related to chemotherapy.

Cura will supply and distribute Mucotrol(TM) with Medivisor handling the marketing and sales. Under the terms of the new agreement both parties agree to now share in the net profits.

“We are pleased to have signed this new sales and marketing agreement with Cura,” stated Dino Luzzi, CEO of Medivisor. “We believe Mucotrol will demonstrate strong commercial interest in the relief of side effects of those patients undergoing chemotherapy treatments.”

About Medivisor Inc.: Medivisor is a medical communications company dedicated to providing concise and timely medical information to healthcare industry professionals. Medivisor exclusively serves the bioscience and pharmaceutical markets, offering specialized medical marketing consulting, graphic design, web site marketing strategy and market research.

About Cura Pharmaceutical: Cura is a privately held pharmaceutical business that develops, distributes and sells innovative and generic pharmaceuticals. It focuses on selected niche specialty markets through the offering of distinctive products and services, which provide distinct unmet medical needs.

About Mucotrol(TM): Mucotrol(TM) is prescribed for the management and relief of pain for Mucositis, which may be caused by chemotherapy or radiotherapy and irritation due to oral surgery. The National Cancer Institute estimates that approximately 300,000 cancer patients in the U.S. suffer from mucositis associated with cancer treatments.

Safe Harbor

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”) including those relating to the roll-out of Cura Pharmaceutical’s Mucotrol. Additionally, words such as “seek,””intend,””believe,””plan,””estimate,””expect,””anticipate” and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the performance ability of the initial units in the field. Further information on Medivisor risk factors is contained in its filings with the Securities and Exchange Commission. Medivisor does not undertake any duty nor does it intend to update the results of these forward-looking statements.

 Contact: Dino Luzzi CEO Medivisor Inc. 326 Walt Whitman Road Huntington Station, N.Y. 11746 Tel: 631.549.7100 Email Contact

SOURCE: Medivisor Inc.

Sheriff’s Department Slated to Reorganize By Aug. 1

By Joanie Baker, Messenger-Inquirer, Owensboro, Ky.

Jul. 24–The Daviess County Sheriff’s Department will soon undergo an organizational restructuring in an effort to better represent the growing roles of administrative staff.

The new format — which will include a fluctuating supervisor’s shift to reduce overtime — will go into effect Aug. 1.

Sheriff Keith Cain said he has been considering the changes for about a year, and the recent departure of some staff members provided an opportune time to begin initiating the plan.

“Fortunately, over the past 30 years, our office has experienced considerable growth, yet our organizational structure has remained relatively unchanged,” Cain said. “The responsibilities of our supervisors, in particular, has expanded considerably.

“These promotions recognize their efforts and ensure compensation more representative of their increased duties,” Cain said.

The new restructure has become necessary with the departure of Lt. Joe Green, who will retire July 31, and several deputies who have transferred to the Owensboro Police Department or moved to federal agencies.

Most of the changes do not involve pay changes, with the exception of the deputies moving into officer positions or officers actually climbing rank.

For example, Capt. Jeff Jones, who is second in command to Cain, will begin using the title Lt. Colonel Chief next week but will not receive a change in pay.

The two lieutenants at the department, J.D. Marksberry and Bill Thompson, will become captains of patrol and criminal investigations, respectively.

One of the recognizable changes will be the using a split-shift supervisor to oversee second and third patrol shifts. Sgt. Ottaway Kirby will become a lieutenant and will either work from 7 p.m. to 3 a.m. or cover any deficiencies in manpower during either of the patrol shifts.

A newly appointed sergeant, Cpl. Barry Smith, will oversee the first shift.

Cain said Kirby’s ability to fill in should help alleviate some of the overtime issues inflicted by last year’s budget cuts that essentially led to the elimination of a deputy’s position.

“This is not the downsizing of the department, but it does help us deal with reduction in staff caused by budgetary restraints,” Cain said.

Other noticeable changes include a sergeant’s position over court security being turned into a lieutenant’s rank to encompass the growing responsibilities of the position at the judicial center.

Sgt. David Underhill will be promoted to that position. Cain said consideration has been made to possibly placing a sergeant under him in the future.

“This rank structure will serve us better than what we have had in the past,” Cain said.

—–

To see more of the Messenger-Inquirer, or to subscribe to the newspaper, go to http://www.messenger-inquirer.com.

Copyright (c) 2008, Messenger-Inquirer, Owensboro, Ky.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Marketplace: New Elk Grove Clinic Offers Urgent Care

By Melissa Nix, The Sacramento Bee, Calif.

Jul. 24–When you can’t get to the doctor, or the emergency room seems foreboding — even if you are simply uninsured — a new Elk Grove clinic can help meet your medical needs.

Elk Grove Urgent Care, at 9045 Bruceville Road, is open 365 days a year from 9 a.m. to 9 p.m.

No appointments are necessary, and patients are seen usually within 20 minutes, said Margaret Kapasi, office manager.

The clinic can treat children and adults suffering from allergies, insect bites, burns, eye injuries, bone fractures and sprains, and other minor illnesses and injuries.

Urgent Care also provides X-rays, flu shots, immunizations and can perform a variety of laboratory tests.

Immigration physicals and travel shots are available by appointment.

“There are different definitions of urgent care,” Kapasi said.

Save for major injuries and diseases — such as heart attacks or strokes, the clinic operates as a small emergency room, she said, and is a lot less costly than a trip to the emergency room.

As for those who are uninsured, the clinic discounts doctor visits and treatment by 30 percent.

For more information, call (916) 479-9110 or visit www.elkgrove-urgentcare.com.

AAA closes center early

AAA of Northern California announced last week that it will close its Elk Grove center by the end of 2010 — a year earlier than expected.

The call center, at 9700 West Taron Drive, opened in 2003 and employs 500 people.

The company has said greater efficiencies can be obtained by moving operations out of the state, to Arizona and Oklahoma, specifically.

The company told The Bee in October that it may offer its Elk Grove employees severance packages, transfers to other sites or into other company positions.

The Elk Grove center, which handles about 200,000 insurance, membership and road service calls per month, will be the last of AAA’s three California call facilities to close. The Livermore site will close Sept. 1; the Irvine site March 2009.

Once the call center closes, the AAA building will be sold, said spokesman Sean Comey.

Bee business columnist to speak

Bob Shallit, a business columnist for The Bee, will be the guest speaker at the Elk Grove Chamber of Commerce membership meeting and luncheon Friday at the Valley Hi Country Club, 9595 Franklin Blvd.

Check-in and networking begins at 11:30 a.m. The luncheon and program begins at noon.

The cost is $25. Chamber members gain entrance for $20.

—–

To see more of The Sacramento Bee, or to subscribe to the newspaper, go to http://www.sacbee.com/.

Copyright (c) 2008, The Sacramento Bee, Calif.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Blue Cross, Fairview at Impasse Over Doctors’ Fees: Patients Worry About Disruptions in Care As Aug. 23 Deadline Nears

By Jeremy Olson, Pioneer Press, St. Paul, Minn.

Jul. 24–Tough negotiating between Minnesota’s largest health insurer and the state’s third-largest health system has patients scrambling to find new doctors and worrying about disruptions to their medical care.

Jennifer O’Hara searched hard to find the right doctor to deliver her first child and felt comfortable with her choice at the Fairview Riverside Woman’s Clinic in Minneapolis. Now the St. Paul woman is considering a switch in mid-pregnancy because her insurer, Blue Cross and Blue Shield of Minnesota, might drop Fairview doctors from its network.

“To deprive myself and your members of the care we currently receive would be a huge disappointment,” O’Hara wrote Blue Cross in a letter.

Blue Cross and Fairview have set an Aug. 23 deadline to agree on payment rates for Fairview’s doctors and outpatient clinics. (They have until late October to negotiate inpatient hospital rates.) If they can’t agree, Blue Cross would pay only out-of-network rates for Fairview care — resulting in much larger bills for patients.

Although leaders on both sides remain hopeful about an agreement, Blue Cross and Fairview have sent letters to affected patients about the impasse. Blue Cross estimates as many as 50,000 of its members have used Fairview clinics or outpatient services in the past year.

Patients wouldn’t be prohibited from using Fairview doctors, but some are taking the letters from Blue Cross as a signal to switch. Pregnant women are rescheduling checkups and

ultrasounds. Parents are finding new family doctors before the school year and the cold and flu season. Cancer patients are parting with doctors they credit with keeping them alive.

Jeanne, of Minneapolis, summed up her feelings in a posting on the Pioneer Press Web site at twincities.com. She said she has relied on numerous Fairview doctors since she was diagnosed with leukemia in 1993, and the relationship with her primary care doctor is tough to replace.

“She knows how compliant you are about taking drugs or following their advice … She knows why you hate having blood drawn or loves hearing her tell you when she doesn’t know something,” she wrote. “None of these things appears on a medical record, which is the only thing that gets transferred when you go to a new clinic.”

Leaders of Blue Cross and Fairview agree the impasse presents hardships for patients, but are sticking to their positions. Fairview is seeking higher payment rates to improve care, contending its requests are comparable to rates paid by other insurers. Blue Cross counters that Fairview wants payments that far exceed what other health systems receive.

In some cases — such as third-trimester pregnancies or ongoing cancer treatment — Blue Cross may extend coverage so patients may stay with their Fairview doctors. People should call the numbers on their insurance ID cards for more information.

Kori Hennessy, of Minneapolis, chose a family doctor to deliver her second child, partly because she liked the idea of one doctor handling the delivery of her son and his medical care as he grows up. When her family had to switch health plans this summer, she chose Blue Cross because it had an open network that included her doctor.

“So when I got this letter,” she said, “I was a little upset.”

Hennessy has set up her 30- and 32-week appointments with her regular doctor, but scheduled the 34-week visit with a new physician — just in case.

“I’m hoping they have made a decision by then,” she said.

O’Hara deals with contract negotiations in her work, so she understands how the process can linger until the deadline. Still, she is frustrated it is disrupting her first pregnancy, now in its 13th week.

The first ultrasound to see if she’s going to have a boy or girl should be coming up in late August, and O’Hara doesn’t know where she will end up. She has used Google and clicked to doctor rating sites online in case she needs a new physician. Although she would like to stay with her doctor, the added co-pays and other costs would be difficult to bear.

“I just can’t justify spending so much more money,” she said, “no matter how terrible it would be to find somebody new.”

Jeremy Olson can be reached at 651-228-5583.

NEED HELP?

If you’re caught in the Blue Cross-Fairview flap, you can:

–Call Blue Cross and Blue Shield of Minnesota at the numbers on your insurance cards.

–Call Fairview at 612-672-7272.

—–

To see more of the Pioneer Press, or to subscribe to the newspaper, go to http://www.twincities.com.

Copyright (c) 2008, Pioneer Press, St. Paul, Minn.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

NASDAQ-NMS:GOOG,

Franciscan Skemp to Open New ER and Urgent Care Center

By Terry Rindfleisch, La Crosse Tribune, Wis.

Jul. 24–Franciscan Skemp Healthcare will open a $9 million center that officials said will change the way emergency and urgent care services are delivered to patients.

The Emergency and Urgent Care Center will open Aug. 6. The 15,000-square-foot facility will be located in the north end of the Center for Advanced Medicine and Surgery on Market Street and West Avenue. “This is a fundamentally different model designed to make sure the patient gets the appropriate care for the complexity of their need,” said Dr. Robert Nesse, Franciscan Skemp president and CEO. “In the past, patients were often put in the position of trying to guess how serious their condition was. Now a triage nurse will make sure they get the right care.”

Patients do a quick registration with name, birthdate and medical problem, and then see a triage nurse who will determine whether they should be “fast-tracked” to urgent care or taken to the emergency department, said Joy Erb-Moser, a registered nurse and EMS education coordinator.

“This model has taken the burden off people making the decision of what services they need,” Erb-Moser said.

Nesse said triage nurses will follow protocols to make their decisions. “Medical costs are part of that decision because the co-pay for emergency care could be double that of urgent care,” he said.

Urgent care services will offered 6 a.m. to midnight.

It is the first renovation project for Franciscan Skemp emergency/urgent care services in more than 30 years.

“The space we had was just inadequate and we couldn’t provide the most efficient care we needed to with the best technology,” Nesse said.

Sue McBride, director of patient care for the emergency and urgent care center, said the center was designed by nurses and medical staff to create better patient flow and more timely and efficient care.

The center has 17 emergency rooms and five urgent care rooms.

McBride said the center has 85 computers and four large electronic boards that keep track of staffing and patients’ status.

Cheryl Paar, trauma coordinator, said the rooms also have electronic patient lifts, toilets and standardized equipment carts.

The center has a special room for treatment of sexually-assaulted women. A laboratory and CT scanner are also located in the center.

Ronald McDonald House Charities of Western Wisconsin and Southeastern Minnesota donated money for a waiting area with original art and a children’s area scaled for younger visitors and supplied with books and activities.

“Our focus for this new center was patient comfort, care and access, combined with the latest technology,” Nesse said. “I like what we’ve done.”

BY THE NUMBERS

Franciscan Skemps Emergency and Urgent Care Center, by the numbers:

– 15,000 square feet

– 22 exam rooms

– $9 million project, including $4.3 million raised by the community and medical center staff

– 58,300 linear feet, or 11 miles of metal studs

– 116,800 feet of wire, long enough to stretch from the new building to Trempealeau, Wis.

– 38,000 square feet of insulation, just enough to cover a football field.

– 98,000 square feet of drywall, enough to cover three football fields.

– 2,400 pounds of lead hung on the walls of the CD scanner and radiography rooms.

– 4,800 hours of labor

Source: Franciscan Skemp Healthcare

New building projects set

Franciscan Skemp Healthcare will break ground July 30 on a new Holmen, Wis., clinic and will soon expand parking at its Onalaska clinic.

The new and bigger clinic in Holmen will be at Holmen Drive and Hale Road, just north of the Pizza Corral restaurant. The clinic is expected to open in spring 2009. Franciscan Skemp will relocate its existing clinic behind Holmen Square to the new site, expanding from 7,500 square feet to 20,000 square feet.

Franciscan Skemp earlier bought 10 acres of land next to its Onalaska clinic and will expand patient parking on some of the land in the fall, said John Nemec, Franciscan Skemp vice president of regional services.

Construction on a new combined cardiology-radiology department at the La Crosse medical center will be finished by spring. A new catheterization laboratory is operating and a new entrance is being constructed. The main entrance to the hospital is also being remodeled.

Nemec said the hospital will undergo major renovation with a conversion to private rooms and reorganized departments in the next five years. The Sparta hospital/clinic will undergo renovation for expansion of clinic and emergency services, he said.

Terry Rindfleisch can be reached at [email protected] or (608) 791-8227.

—–

To see more of the La Crosse Tribune or to subscribe to the newspaper, go to http://www.lacrossetribune.com/.

Copyright (c) 2008, La Crosse Tribune, Wis.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

New Hospital Prepares to Open Sunday in Petersburg

By Luz Lazo, Richmond Times-Dispatch, Va.

Jul. 24–PETERSBURG — After two years of construction, the new Southside Regional Medical Center hospital building — a $125 million project on the southeast edge of the city — is ready to open Sunday.

That’s when an entire operation in the planning for about a year will take place: About 200 patients will be transported every 90 seconds from the hospital on South Adams Street to the new facility on Medical Park Boulevard off South Crater Road.

If all goes well — no inclement weather or issues with roads, for instance — all patients will be at the new building by 10 a.m. Sunday, hospital Chief Executive Officer David J. Fikse said.

Hospital staff have been working long hours in the past two weeks to get the new building ready for the move. Contractors have moved equipment and medical records, and employees have been testing new equipment while getting acquainted with the five-story, 420,000-square-foot building.

“The biggest thing that we have done is spending time in planning,” Fikse said.

The facility is expected to be an asset to the entire region, he said. “This is part of the new beginning in the Tri-Cities. It’s kind of a fresh start.”

Surrounding localities depend heavily on Southside Regional’s services, and the old building, which opened in 1953, was showing some deterioration and was too small for a community that is growing, Prince George County Supervisor Jerry J. Skalsky said.

The South Crater Road corridor already is experiencing a surge of development as a result of the hospital. Several projects are under way including construction of a medical building, City Manager B. David Canada said.

“The facility will be an economic drive,” Canada said, noting that the city has several proposals for retail shops, apartment buildings, and other commercial development in the same general area.

While area leaders praise the hospital’s economic potential, hospital officials also point out the new technologies that will mean better services to the community.

A new beeper system will alert relatives when their loved one comes out of surgery, when the doctor needs to talk to them, and when it is time to be discharged, said Terry Tysinger, director of marketing and public relations.

Waiting for a patient will be less stressful, Tysinger said. “This system gives the patients and their families a little bit of peace of mind.”

But the beeper is just one of several technologies in the new building. Rooms will have flat-screen television sets; doctors will have access to a computer program that will allow them to access images and reports immediately; and hospital staff will be able to use an automatic tube system to deliver lab samples and prescription drugs quickly.

The new hospital has 300 beds; an expanded emergency department with 32 beds, three nursing stations, two trauma rooms and two cardiac-care rooms; and an expanded neonatal intensive-care unit, hospital officials said.

These technologies will make patients’ stays more comfortable and will help hospital staff provide more efficient and immediate service, Tysinger said.

Contact Luz Lazo at (804) 649-6058 or [email protected].

—–

To see more of the Richmond Times-Dispatch, or to subscribe to the newspaper, go to http://www.timesdispatch.com.

Copyright (c) 2008, Richmond Times-Dispatch, Va.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Paul Capital Partners Promotes Ken Macleod To Partner

NEW YORK, July 24 /PRNewswire/ — Paul Capital Partners today announced that Ken Macleod, Ph.D., has been promoted to Partner. Based in Paul Capital’s London office, Dr. Macleod is responsible for sourcing, evaluating and negotiating European and Asian healthcare investment opportunities for the Paul Capital Healthcare funds.

“Since he joined Paul Capital four years ago, Ken has strengthened our presence in the European and Asian healthcare markets and helped us form many mutually beneficial partnerships,” said Walter Flamenbaum, M.D., a Partner of Paul Capital Partners. “He embodies our commitment to helping healthcare companies, institutions and inventors advance their goals by identifying strategic solutions to their financial and asset management needs. Ken’s promotion to Partner reflects his demonstrated ability to identify promising healthcare investment opportunities and underscores Paul Capital’s dedication to expanding its position in the global healthcare arena.”

Most recently, in April 2008, Paul Capital Healthcare invested up to $28 million in Plethora Solutions Holdings PLC and euro 18.4 million in Vernalis plc, both of which are based in the U.K. To date, the Paul Capital Healthcare funds have invested $395 million in 14 transactions in Europe and Asia.

“A growing number of European and Asian healthcare companies and institutions recognize that in order to realize their innovative potential they require an equally innovative approach to creating value and accessing capital,” said Dr. Macleod. “With more than $940 million committed to 37 healthcare investments, and similar leadership in the areas of private equity secondaries and venture capital funds of funds, Paul Capital provides funds that help leading-edge companies, institutions and individuals meet diverse strategic objectives. I am very pleased to become a partner of this highly regarded team.”

Dr. Macleod provides a strong operational background in the pharmaceutical and biotechnology industries, where he previously held senior management positions over a 15-year career at Serono, Abbott Laboratories and Beecham Pharmaceuticals. Prior to joining Paul Capital Partners, Dr. Macleod was a Venture Partner at Schroder Ventures Life Sciences where he was responsible for deal sourcing, evaluation and negotiation of pharmaceutical investment opportunities. Dr. Macleod earned his Ph.D. from the University of York, UK and his B.Sc. with honors in Biology from the University of Manchester, UK.

About Paul Capital Partners and Paul Capital Healthcare

Founded in 1991, Paul Capital manages $6.6 billion in capital commitments for its three investment platforms that include private equity secondaries, healthcare royalty and revenue interests, and venture capital fund of funds. The firm has offices in Hong Kong, London, New York, Paris, San Francisco, Sao Paulo and Toronto.

Through its funds, Paul Capital Healthcare is one of the largest dedicated healthcare investors globally, with more than $1.4 billion in equity capital commitments and debt facilities under management. Combined, the Paul Capital Healthcare funds have invested more than $940 million in the pharmaceutical, biotechnology, and medical device sectors. These investments are focused on commercial stage companies and products, and consist of investments in the form of royalties, revenue interests, debt and equity. Additional information on Paul Capital Healthcare can be found at http://www.paulcapitalhealthcare.com/.

   Contact:   Paul Capital Partners   Ken Macleod, Partner   Tel: +44(0)20-7514-0754   Email: [email protected]    Joshua Glaser, Director of Investor Relations   Tel: +1-646-264-1169   Email: [email protected]    Lazar Partners   Stephanie Seiler   Tel: +1-646-871-8487   Tel: +1-206-713-0124   Email: [email protected]  

Paul Capital Partners

CONTACT: Ken Macleod, Partner, +44-20-7514-0754, [email protected],or Joshua Glaser, Director of Investor Relations, +1-646-264-1169,[email protected], Paul Capital Partners; or Stephanie Seiler of LazarPartners, +1-646-871-8487, +1-206-713-0124, [email protected]

Web site: http://www.paulcapitalhealthcare.com/

Court Holds California’s Homeschoolers in Suspense

By Greenhut, Steven

Anyone interested in the nearly criminal mismanagement of the nation’s government-run schools need only do research on the acronym LAUSD. In March 2006 Los Angeles Mayor Antonio Villaraiogosa gave a speech blasting the LAUSD-Los Angeles Unified School District-for its “culture of complacency” and described the dropout problem in the district as “the new civil rights issue of our time.” These aren’t the words of a conservative education reformer, but of a liberal Democratic mayor with close ties to the teachers’ union. He is the latest in a string of LA mayors who have tried to deal with a school system that’s immune from serious reform, not to mention unable to keep students safe. I offer this as a background to an article on homeschooling for this simple reason: California officials operate some of the worst education bureaucracies in the nation. Yet some officials here are concerned not so much with the government-run schools, but with the possibility that a fraction of the state’s students are being educated by their non-credentialed parents at home. This is the “let no flower bloom” approach to public policy, as government officials and public-sector unions react against small private successes in their midst, mainly, I suppose, because of the embarrassment it entails. If for a few bucks a year parents can teach kids who go on to excel in state tests, get accepted to Berkeley, and win spelling bees, then why can’t the professional “educators” do as well with $11,000 or more per student each year taken from taxpayers?

In California this issue of homeschooling had been dormant for about five years, after the current superintendent of public instruction overruled his predecessor’s policy of harassing homeschools. But a February ruling by the state district court of appeal brought back reminders of the bad old days after it ruled that “parents do not have a constitutional right to homeschool their children. . . . Because parents have a legal duty to see to their children’s schooling within the provisions of these laws, parents who fail to do so may be subject … to imposition of fines or an order to complete a parent education and counseling program.” The court even issued a threat to parents that they could lose custody of their children if they persist in teaching them at home: “the juvenile court has authority to limit a parent’s control over a dependent child.”

This ruling-which stemmed from a Child Protective Services action against a Los Angeles County homeschooling parent accused of physically and emotionally harming his kids-was remarkably broad and viewed by most observers as outlawing homeschooling. My newspaper columns argued that parents had much to fear from the ruling, which could give local school districts the rationale to declare homeschooled kids truants. The case needs to be overturned, but two significant things happened in the ensuing weeks.

First, although the California Teachers Association celebrated the ruling, prominent Republican and Democratic politicians rebuked it. Gov. Arnold Schwarzenegger vowed to push for a legislative fix, but he seems unclear on what course his administration is going to take. More important, the superintendent of public instruction, Jack O’Connell, declared that homeschooling is legal and that his department would respect the choices made by homeschooling parents.

Second, in the wake of such political and public outrage, the court of appeal vacated the ruling and said it would rehear the case. It will take months to get a new ruling, but homeschool families are safe for now, and it’s likely that any new ruling will be tailored in a narrower manner. Homeschoolers still have reason for worry, though, so it’s worth looking closely at how such a basic freedom could come under a sustained government assault.

The good news is that the homeschooling landscape has changed significantly in California in the past five years. In a February 2003 Freeman article, I described “California’s War on Homeschoolers” under then-Superintendent Delaine Eastin. A teachers’ union ideologue (who lacked a teaching credential herself.), Eastin believed homeschooling to be illegal and was dedicated to stamping it out. She argued that parents who homeschooled needed a state teaching credential, even though at the time about 13 percent of public-school teachers in California lacked one.

The problem: California law then, as now, is unclear on the issue of homeschooling. The state has compulsory-education laws that require government schooling for minor children unless they attend private schools or are tutored by someone with a teaching certificate or meet some other narrow exceptions. Foes of homeschooling argue that homeschooled kids don’t meet any of those exceptions. But homeschool defenders point to another section of the education code: “Children who are being instructed in a private full- time day school by persons capable of teaching shall be exempted” from the compulsory-education law.

Legislation and Unions

In an ideal world (or some place more rational than the California legislature), some sort of legislative clarification would be welcome, but homeschooling families and their defenders have been correctly frightened by such a direct approach. They understand that the teachers’ unions, which have much power in both houses of the Democratic-dominated legislature, could easily steer such a “fix” into a direct banishment of homeschooling, which could leave families far worse off than they are now.

So homeschoolers and most school districts-which ultimately decide whether to pursue cases against truants-embraced a sort of “don’t ask, don’t tell” work-around. Parents registered their homeschools as private schools or enrolled in a private or charter school, then taught their kids in a home-study program. Those who chose to call themselves private schools filled out a private- school affidavit at their local county department of education. The occasional department challenged this, but most did not.

But in 2002 the state Department of Education adopted a change in how parents were required to file those affidavits. Instead of filing with their county education departments, parents were told to file the affidavits directly with the state’s department online. It sounded simpler, but homeschoolers got nervous, given the department’s position on homeschooling. To make matters worse, Eastin sent a letter to the local departments explaining the state’s policy regarding the new private-school filing procedures:

“As generally understood, the term homeschooling describes a situation in which non-credentialed parents . . . teach their own children, exclusively, at home, often using a correspondence course or other types of courses. Defined in this way, homeschooling is not authorized in California, and children receiving homeschooling of this kind are in violation of the state’s truancy laws.”

Eastin was clear. The “not authorized in California” line is a giveaway. Yet she denied that she was using her post to outlaw homeschooling.

Fortunately, Eastin’s term ended soon after this, and she left the state. Although he was noncommittal during his campaign for superintendent, former legislator Jack O’Connell quickly put the kibosh on Eastin’s antihomeschool efforts after he was elected. He said he believed in homeschooling as a choice in education, and homeschoolers have operated in peace until the court decision in February.

The Rachel L. case should send shivers down any freedom-lover’s spine. Three judges-two Republican appointees and one Democratic appointee-not only denied that there is any right to homeschool in California, but described education and the role of parents in starkly big-government terms. The case also gives disturbing insight into the state of parental rights in America today.

In giving the case background, the judges explained that the family’s eldest child reported physical and emotional mistreatment by the father: “The Los Angeles County Department of Children and Family Services investigated the situation and discovered, among other things, that all eight of the children in the family had been homeschooled by the mother rather than educated in a public or private school.”

In a footnote the court explained that one of the explanations the parents offered for not sending their kids to school was that “educating children outside the home exposes them to ‘snitches.’ ” The court seems to be mocking the parents here, but Leslie Heimov, executive director of the organization that represented the family’s two children in the case, told the San Francisco Clironiclc that “her organization’s chief concern was not the quality of the children’s education, but their ‘being in a place daily where they would be observed by people who had a duty to ensure their ongoing safety’ ” (emphasis added). So the winning party in the case argued directly that education per se wasn’t at issue, only the ability of outsiders to monitor what was going on inside this particular family’s home.

The State’s View of Education

The court then quoted the California Constitution, which states: “A general diffusion of knowledge and intelligence being essential to the preservation of the rights and liberties of the people, the Legislature shall encourage by all suitable means the promotion of intellectual, scientific, moral, and agricultural improvement.” Based on that sentence, the court echoed this point from an earlier case: “In obedience to the constitutional mandate to bring about a general diffusion of knowledge and intelligence, the Legislature, over the years, enacted a series of laws. A primary purpose of the educational system is to train school children in good citizenship, patriotism and loyalty to the state and the nation as a means of protecting the public welfare.” Read that again for full effect: A primary purpose of education is train children to be loyal to the state! This is ironic, because when libertarian critics of public education argue that the main goal of public education is not to teach, but to promote the government or to propagandize, we are mocked as extremists. Yet the court’s own opinion supports this view.

Here’s the court explaining why private schools are acceptable, but homeschools are not, based on what is known as the Turner case (1953): “The court observed that whereas it is unreasonably difficult and expensive for a state to supervise parents who instruct children in their homes, supervising teachers in organized private schools is less difficult and expensive.”

The sole focus of the court was the prerogative of government. The above statement is most telling, in that it mentions nothing about the rights of the people and is committed to approving a scenario that is most convenient for the government. Have things really gotten this bad?

But as bad as this case has been, some homeschooling advocates told the public not to worry. They argued that the appeals court’s decision here was narrow and only dealt with one family that happened to homeschool through a home-study arrangement with a religious school. One blogger, called Ace of Spades, argued, “If only the parents had attempted to homeschool their kids in one of the statutorily prescribed methods, they would have prevailed.” It’s just one opinion, of course, but the blog post was e-mailed widely- even by homeschool supporters who wanted to reassure fellow homeschoolers that they had nothing to worry about. But falsely reassuring people is no better than unnecessarily scaring them. Most legal authorities on both sides of the issue, however, agreed that the ruling could spell trouble for the state’s homeschoolers.

Those who echoed Ace of Spades’ reasoning clearly misunderstand California’s law regarding homeschooling. Parents could not simply follow “statutorily prescribed methods” for homeschooling because there are no clear statutorily prescribed methods. The law is unclear, which leaves parents dependent on the latest interpretations of state officials. The court ruling gives ammunition to districts that might want to take a negative view of homeschooling.

By striking down homeschooling through a private-school program, the court attacked one of the main ways parents homeschool in this state. Parents can enroll their kids in private or charter schools, the court argued, but their kids must actually go to those schools and not be schooled instead at home, unless the tutor or parent has a government teaching certificate (something few parents have or even would want). No wonder most homeschool families have been alarmed by the decision; it seems to undermine the way most of them operate within the current system.

The Scope of the Decision

“The scope of this decision by the appellate court is breathtaking,” said Brad Dacus, president of the Pacific Justice Institute (PJI) in Sacramento, which defends homeschool families. “It not only attacks traditional homeschooling, but also calls into question homeschooling through charter schools and teaching children at home via independent study through public and private schools.”

Fortunately, homeschoolers got agitated at the decision and the state’s political establishment reacted appropriately. Right after the decision was publicized, I called O’Connell’s office and his spokeswoman emphasized that the superintendent supports homeschooling as an educational choice.

The superintendent issued a statement: “I have reviewed this case, and I want to assure parents that chose to homeschool that California Department of Education policy will not change in any way as a result of this ruling. Parents still have the right to homeschool in our state. . . . As the head of California’s public school system, I hope that every parent would want to send their children to public school. However, traditional public schools may not be the best fit for every student. . . . [Sjome parents choose to send their children to private schools or to homeschool, and I respect that right. I admire the dedication of parents who commit to oversee their children’s education through homeschooling.”

That statement was exactly what was needed. It reinforced that the state still considers homeschooling legal, and it was respectful toward the “right” parents have to homeschool. This was great news, especially coming from a prominent Democrat who is running for governor.

Furthermore, the current Republican governor said, “Every California child deserves a quality education and parents should have the right to decide what’s best for their children. Parents should not be penalized for acting in the best interests of their children’s education. This outrageous ruling must be overturned by the courts and if the courts don’t protect parents’ rights then, as elected officials, we will.”

Then came word that the court would rehear the case.

The outcry against the case has been broad, and news of the court’s reconsideration was well-received. My sense is homeschooling has come into its own in the last few years-so much so that it’s harder to attack now than it was in 2002, when Eastin was trying to treat homeschoolers as truants. Eternal vigilance remains the key to preserving fundamental liberties. And what is more fundamental to the idea of a free society than the ability to teach one’s children at home without the prying eyes and approval of the state?

Homeschoolers will be watching the rehearing closely.

If for a few bucks a year parents can teach kids who go on to excel in state tests, get accepted to Berkeley, and win spelling bees, then why can’t the professional “educators” do as well with $11,000?

By striking down homeschooling through a private-school program, the court attacked one of the main ways parents homeschool in this state.

What is more fundamental to the idea of a free society than the ability to teach one’s children at home without the prying eyes and approval of the state?

Steven Greenhut ([email protected]) is a columnist for the Orange County Register in Santa Ana, Calif.

Copyright Foundation for Economic Education, Incorporated May 2008

(c) 2008 Ideas on Liberty. Provided by ProQuest Information and Learning. All rights Reserved.

Dietary Carbs and Eye Health

By Taylor, Allen

Loss of central vision is an early sign of age-related macular degeneration (AMD)-which is one of the leading causes of blindness among the elderly. Another kind of vision loss, sometimes occurring in people with diabetes, has been associated with consumption of diets high in “fast” carbs. These carbohydrates are quickly digested and absorbed, resulting in a rapid rise and fall in blood sugar levels. Fast-carb foods include white bread, rice, potatoes, pastas, sugars, and syrups. But whole-grain versions of bread and pasta, and brown rice are considered “slow” carbs and are digested more slowly. Researchers analyzed data taken from more than 4,000 men and women, aged 55 to 80, who are participating in the Age- Related Eye Disease Study. They want to know whether the type of damage to eye tissue produced by fast carbs is similar in both AMD and diabetic eye disease. The goal is to find modifiable risk factors that can help prevent or reduce the effects of aging on eye health. Allen Taylor, USDAARS Laboratory for Nutrition and Vision Research, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts; phone (617) 556-3156, e-mail allen. [email protected].

Allen Taylor, USDAARS Laboratory for Nutrition and Vision Research, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts; phone (617) 556-3156, e- mail allen. [email protected]. Copyright Superintendent of Documents Jul 2008

(c) 2008 Agricultural Research. Provided by ProQuest Information and Learning. All rights Reserved.

Heart Attack Patients Are Put on Faster Route to Treatment

UP TO 150 North Yorkshire patients a year could benefit from a new scheme to fast-track specialist treatment for serious heart attacks to Leeds -and spare victims from having to undergo a double journey.

Until now all people experiencing cardiac symptoms have been taken to their local hospital first to be assessed. Then if they need a specialist procedure to clear the blockage they are put back in the ambulance to go to Leeds General Infirmary.

Now North Yorkshire and York Primary Care Trust (PCT) bosses want to speed up the process and get many patients the help they need faster by giving ambulance service paramedics the call on where they think the patient should go.

If the paramedic realises that the patient needs the specialist treatment to clear the blockage, called angioplasty – which can only be performed at the LGI – the patient can be sent straight there.

The PCT’s director of commissioning and service development Jane Marshall said: “This new service could potentially benefit up to 150 people from York and Harrogate each year as heart attack patients now have much quicker access to angioplasty procedures.

“This new fast-track service will ultimately give patients the best possible chance of a full recovery.”

At present the changes are limited to York and Harrogate areas because one of the criteria is the patient should arrive at the LGI within two hours of the paramedics attending.

If it takes longer to stabilise the patient at home, being put straight on an ambulance to go for surgery is probably not the kindest way to treat them. So they will go to their local hospitals and be transferred to the LGI when they are well enough.

The PCT says it has been working closely with the ambulance paramedics to deliver the new service, which has already started in York and Harrogate areas and may be rolled out to more remote parts of North Yorkshire once officials have seen how it is working.

It is limited to heart attacks classed as a STEMI (ST elevated myocardial infarction): the most severe type of heart attack caused by complete blockage of a coronary artery, causing irreversible damage in minutes. A less severe heart attack is known as a Non- STEMI.

Yorkshire Ambulance Service medical director Dr Alison Walker said: “If a paramedic identifies a patient as having had a STEMI, the sooner the primary angioplasty is carried out, the less damage there will be to the heart and the quicker the patient is likely to recover.

“YAS is pleased to be involved in this service and there has been excellent co-operation between the ambulance service, North Yorkshire and York PCT and Leeds General Infirmary providing this service 24 hours a day.”

A trust spokesman made clear there was no intention of the service taking anything away from local hospitals, adding: “If they need an angioplasty the only place it can happen and best place for them is the LGI and they would be transferred there anyway.

“If someone presented with severe chest pains under the old system the paramedic would take them to local hospital to be stabilised and assessed. They would then be transferred to the LGI, and so incur two journeys.

“Now if the paramedics arrive and diagonise the patient is having a particular type of attack which requires this procedure and can guarantee they can get that person to the LGI in two hours they will take them there.

“The LGI will liaise with the local hospital about transferring the patient back to their local hospital for rehab. It is just trying to speed things up for patients to get them the procedure faster.”

(c) 2008 Yorkshire Post. Provided by ProQuest Information and Learning. All rights Reserved.

Nurse Struck Off for Series of Blunders

An overworked nurse who claimed she made a string of errors while ‘stressed beyond endurance’ has been struck off.

Jolanta Nowak, 54, boycotted the misconduct hearing in London after calling the investigation a ‘show trial of which Stalin would have been impressed’.

Nowak admitted to a series of blunders at the Cheltenham General Hospital between March 2003 and February 2005 including failing to give patients their drugs and not filling out charts.

On one occasion she gave a male patient a double dose of a naso- gastric feed after forgetting she had already given him one.

The man struggled for air on the feed after the incident on February 9, 2005.

Husband Chris Nowak, 54, read out a statement to the Nursing and Midwifery Council prepared by his wife, claiming she was in a ‘no- win situation’.

She said: ‘On many occasions I noticed that I, as an ordinary Grade D, was scheduled to work as the sole qualified nurse on this supremely busy ward for several shifts in succession, something my colleagues were not asked to do.

‘At such times I remember being stressed beyond endurance.

‘I put this scapegoating down to the fact that I have a tendency to speak my mind.

‘ I believe I was being placed deliberately under yet further stress in order to generate so-called ‘errors’ on my part.

The first of the mistakes happened on March 15 and 16, 2003, when Nowak failed to fill in a patient’s care chart.

Two days later, on March 17, Nowak failed to give a cardiac patient his medication to treat heart failure, and another nurse had to give the drug more than four hours late.

On July 28, Nowak again failed to give two drugs to a patient, one a beta-blocker and one a mineral supplement – again it was given late by another nurse.

Nowak claims the proceedings have been biased against her and urged fellow nurses to boycott their NMC hearings.

She said: ‘I have lived under communism and I recognised a show trial when I see it. Stalin would have been impressed.

‘The hearing and all its precursor processes are intentionally skewed against me.

Nowak resigned from Cheltenham General Hospital in March 2005 and was told on April 15 she had been referred to the NMC for misconduct.

But after a gap of up to two months at the end of June, her husband believed there was no chance of the NMC continuing the case.

To cheer his wife up and put the whole thing behind them, Mr Nowak decided they should burn all the documents in the back garden.

Mr Nowak left the hearing before he heard panel chair Linda Read rule that his wife’s fitness to practice was impaired as a result of her misconduct.

Ms Read said the panel ‘frankly do not accept’ the registrant’s claims that she was bullied into her mistakes.

She said: “In the basic areas of her practice, the registrant fell far below the standard expected of a registered nurse.

“We are concerned the registrant has admitted the facts in a qualified way.

“It is clear from her written statement that she is still not prepared to take responsibility for her actions.”

(c) 2008 Gloucestershire Echo, The. Provided by ProQuest Information and Learning. All rights Reserved.

MediVoice(R) Partners With VisionTree(R) to Integrate Its Voice-Activated E-Prescribing Solution Into VisionTree’s VTOC(TM) Web-Based Patient Management System

WHITE PLAINS, N.Y., July 24 /PRNewswire/ — MediVoice(R), LLC, the world’s first mobile voice-activation solution for e-Health and e-Prescribing, has formed a strategic partnership with VisionTree(R), a leading provider of interactive, web-based, patient-centered health record management and provider communication systems to integrate and market its mobile voice-activation solution with the VisionTree Optimal Care(TM) (VTOC) system.

“MediVoice is pleased to develop a strategic partnership with VisionTree. We are impressed with their web-based technology and the value it brings to physicians and patients,” said Anthony Milone, MediVoice, LLC, Board Member and Managing Director.

VisionTree customers will be able to utilize MediVoice’s software platform to access the SureScripts(R) network for e-Prescribing and e-Health management. MediVoice provides the world’s first commercially available mobile voice-activated e-healthcare solution. MediVoice utilizes the most innovative technology in speech solutions. It allows healthcare professionals to voice-activate electronic prescriptions, electronic medical records, and a wide variety of e-health services. The use of e-Prescribing has been shown to reduce medical errors, reduce medical and administrative costs, and improve the efficiency and documentation of the medication prescription process.

Martin Pellinat, CEO of VisionTree Software, said “The VisionTree Optimal Care(TM) (VTOC) platform is used by over 70 leading academic and community sites around the country for web-based patient communication and data management. With the ability for physicians to launch a voice-activated e-Prescribing solution, we have expanded the VTOC patient management system to not only include the patient’s health record, e-communication and disease management, but also include the ability for physicians to deliver the highest level of efficiency and quality care to their patients.”

Ed Zecchini, COO & CTO of MediVoice adds, “The ease of use of a voice solution will be the driving force for rapid deployment, adoption and utilization of the VisionTree Optimal Care(TM) system and MediVoice’s electronic prescriber.”

“VTOC helps both healthcare consumers and providers,” said Martin Pellinat, CEO of VisionTree. “The system empowers patients to provide important feedback directly with their physician electronically, as well as build their own personal health record to help make the best decisions at the most critical times. VTOC will also serve as the vehicle to transform the medical industry into a true paperless environment, increasing staff’s productivity and data gathering capabilities to effectively measure patient satisfaction. With more than 100,000 users, VTOC is improving the way healthcare is offered.”

About VisionTree(R) Software

VisionTree Software, Inc. is the leader in web-based, patient-centered health record management, communication and data collection systems. VisionTree’s Healthcare Solutions consist of VisionTree Optimal Care(TM) or VTOC, VisionTree MOC Online(TM) and VisionTree Clinical Trials(TM) for Web-based data collection, efficient workflow, as well as improved communication, documentation and quality of care. VisionTree’s customer base consists of leading academic and community healthcare organizations across the country. For more information, visit http://www.visiontree.com/.

About MediVoice(R)

MediVoice provides the world’s first commercially available mobile voice-activated e-healthcare solution. The company enables stakeholders in the healthcare industry to have a low-cost, rapidly deployed solution for its caregivers. Utilizing the most innovative technology in speech solutions, MediVoice allows healthcare professionals to voice-activate electronic prescriptions, electronic medical records, and a wide variety of e-health services. For more information, visit http://www.medivoicerx.com/.

(C) 2008, MediVoice, LLC. All Rights Reserved. VisionTree is a trademark of VisionTree Software, Inc. in the United States.

   Contact:   MediVoice, LLC   Anthony Milone   (914) 328-3402   [email protected]  

MediVoice, LLC

CONTACT: Anthony Milone, MediVoice, LLC, +1-914-328-3402,[email protected]

Web site: http://www.medivoicerx.com/http://www.visiontree.com/

Doctors’ Drugs Cocktail Blunder Cut My Son’s Life Short, His Mother Tells Coroner

A GIFTED disabled boy died after doctors mistakenly gave him a “cocktail of drugs” forbidden by medical textbooks, an inquest heard.

Alexander Newton, 18, a talented scientist, botanist and chess player despite having life-limiting Duchenne’s muscular dystrophy, suffered delusions of being a dog after taking the medication, his mother told a coroner.

Muscular dystrophy expert Dr Philip Jardine said the respiratory arrest caused by the sedative Zopiclone and the painkiller Co- codamol was “a factor” in the boy’s death.

He said he recommended melatonin to help the teenager sleep rather than those drugs, but doctors at the Royal United Hospital, in Bath, Somerset, “disregarded” his advice.

He said sedatives like Zopiclone would lower the blood oxygen levels of the teenager, whose disability already put his life on a “knife edge”.

But pathologist Dr Hugh White said the drugs did not cause his death. He said Duchenne’s sufferers experience a progressive deterioration in muscle function and had a lifespan of around 20 years.

Pamela Newton said doctors readily confessed they had “made a mistake” in the treatment of her son.

The teenager, of Corston, near Bath, died from cardio- respiratory failure 16 days after being admitted in November, 2005.

He was suffering breathing difficulties and was given the drugs but suffered a respiratory arrest.

The family’s solicitor said the doctors at the hospital needed only to look in the British National Formulary, which shows how medicines react with various conditions, to see the “cocktail” could be lethal.

Mrs Newton said in a statement to the hearing in Bristol: “We felt his life was cut short by the poor standard of care by the Royal United Hospital in Bath. We truly feel he would have lived another two or three years had he not been given a sedative and painkiller. He deserved better.”

The inquest continues.

(c) 2008 Yorkshire Post. Provided by ProQuest Information and Learning. All rights Reserved.

The End of the Bender?

By Rob Sharp

Oi! Amy! Put that glass down! Haven’t you heard that the days of rock’n’roll excess are over? As more and more public figures forsake alcohol in the name of health and sanity, and thousands of us follow suit, Rob Sharp explains why society is embracing sobriety

Never has being dry been more fashionable. Sobriety is in vogue – and in Celebrityland, everyone’s at it. Perhaps it’s a sign of the times: a psychosocial response to the credit crunch, a reaction against the millennial excesses of the early Noughties. But suddenly, it seems, clean-living role models are all around us.

For every pie-eyed party animal pictured leaving Chinawhite at 3am, there’s a Chris Martin, a Natasha Kaplinsky, a Catherine Tate. Amy Winehouse may still be keeping the gossip columnists busy, but more and more of her partners in pop are sticking to the San Pellegrino and taking an early cab home.

Little Britain’s David Walliams, a noted man about town, is never seen with anything other than mineral water in hand. Former Blue Peter presenter Konnie Huq may frequently be seen bouncing out of The Ivy, but in full control of her faculties. Note, too, the clear skin and bright eyes of the “alcohol intolerant” newsreader Kaplinsky, or Simon Amstell, presenter of television quiz show Never Mind the Buzzcocks, who also eschew all poisons.

The list goes on. Tate hates the “loss of control” she experiences when drinking. Martin of Coldplay, his missus, Gwyneth Paltrow, and The X-Factor’s massively successful songstress Leona Lewis are noted abstainers.

And sobriety isn’t just a celebrity-specific trend. Members of high society and politics alike are (and have) clean livers. Prince Andrew, French President Nicolas Sarkozy and the leader of the free world himself, George W Bush, have joined the club.

And then there are the sports stars. Needless to say, all- nighters aren’t conducive to being on top of your game, which probably explains why tennis ace Andy Murray is teetotal. Boxer Ricky Hatton abstains for most of the year before a fight, letting down his guard only for a brief, post-fight celebration (and who can blame him after spending 12 rounds getting his head punched in?).

In Hollywood, the actor Jared Leto recently described how he’s more interested in putting on a good show with his band 30 Seconds to Mars than exploring the more hedonistic side of rock. Sober nights out wouldn’t be dull in LA, of course, Leto could socialise with fellow abstainers Jim Carrey, Tobey Maguire, Natalie Portman, Bruce Willis and Samuel L Jackson.

So are all these stars at the vanguard of a new post-alcohol era? Despite the widespread perception of a binge drinking culture in Britain, official statistics seem to suggest this is wide of the mark. In a recent study, the Institute of Alcohol Studies found that a growing number of Britons are abstaining from drink.

The Office for National Statistics agrees. Its most recent survey found the percentage of non-drinking women increased from 41 to 44 per cent between 1998 and 2006. For men, the numbers increased from 25 per cent in 1998 to 29 per cent. And believe it or not, the trend is borne out among underage drinkers. The number of boys aged between 11 and 15 who had never drunk alcohol rose from 38 to 46 per cent. With girls, the figures for non drinkers increased from 42 to 46 per cent.

All of which makes the antics of Rolling Stone Ronnie Wood especially striking. The 61-year-old rocker’s recent drunken sojourn in Ireland, in the company of a 19-year-old Russian waitress, was as retro as it was rock’n’roll. When actor Rhys Ifans drowned his sorrows after splitting from Sienna Miller, he attracted as much opprobrium for his drinking as sympathy for his emotional distress. Peaches Geldof, three sheets to the wind again? Oh dear.

So what’s behind the new vogue for clean living? Jessica Callan, author and former Daily Mirror gossip columnist, insists that there are no hard and fast rules as to why celebs are choosing to live clean.

“There are various reasons why celebrities choose not to drink,” she says. “Some choose it for weight reasons – to pursue various diets, such as a macrobiotic diet – others, Chris Martin for example, choose to abstain because they simply can’t handle alcohol. I interviewed him once and he said the reason he didn’t drink was that he was a total lightweight.

“But generally, celebrities are control freaks. They don’t drink because they don’t want to slip up. David Walliams has been tagged in various newspapers as something of a ladies’ man, which makes him a target for a kiss-and-tell sting. And as he does serious acting as well as comedy, he doesn’t just want to be known for his love life.”

Alexandra Shulman, editor of Vogue, believes that a reduction in people’s consumption of drink and drugs is reflected in the popularity of the detox, essentially the recent trend for taking spa breaks. “The trend for going off to a spa and then coming back and steering clear of alcohol and rich food is a relatively fashionable and new phenomenon,” she explains.

“So many more people are detoxing now. Everyone I know seems to go off to a health retreat once a year, certainly over the past five years.

“What one forgets is that people don’t really stop drinking in their twenties. When they reach their late thirties, however, people begin to think about the effect drinking and partying hard is having on them. Additionally, there’s more pressure on people nowadays to look great while still being able to party – and one way of doing this is by detoxing regularly.”

The former Blur bassist and one-time legendary Soho party animal Alex James reckons the reason he curbed his notoriously excessive lifestyle was growing up and having children. The Noughties, he says, are less of a “party” decade than the Nineties.

“You can’t be sloshing out the champagne in these credit-crunch days. Going on a good bender also needs a lot of time. You need to book a lot of space in the diary. Nowadays, people seem to want to get up and out in the mornings. I’ve gone from being a creature of the night to a daytime person. Of course, many of my friends also started having kids, which kind of disrupts the hedonism somewhat,” he says.

“Adults make babies and babies make adults. Ronnie Wood is one of the best people to get pissed with, but he’s a Rolling Stone. My boozing and shagging was cured by getting married. I changed as a person and my circumstances changed. Now I have something to come home to and responsibilities. It’s getting old and boring that does it.

“It’s brilliant in your twenties to be pissed and fabulous at 11 in the morning. But how old is Ronnie? He’s about 82, isn’t he? There just seems to be something a little bit wrong in that.”

However, while more people are abstaining from drinking, the reasons are complex, according to Dr Rachel Seabrook, research manager for the Institute of Alcohol Studies. “Drinking behaviour is complex and affected by many things, including cultural and economic factors. While the evidence that increasing numbers of people aren’t drinking alcohol is very welcome, more research is needed into why,” she says.

One reason for the spread of sobriety is almost certainly the growth of alternative lifestyle philosophies. “New puritanism” resurrects Cromwellian ideals of abstinence. Adherents shun the consumer society, binge drinking, junk food, smoking and cheap flights in favour of a more wholesome way of life.

The straight edge movement, a recent import to Britain, is inspired by the Eighties’ American punk band, Minor Threat. Those involved (and there’s a substantial following in the UK) avoid drink, drugs and promiscu-ous sex. Straight edgers often draw a black cross on their hand, replicating the stamps given to under- 21s attending gigs in the US (the cross is an indication to bartenders they should not be served alcohol).

Of course, for every back-handed cross, there is a drug or alcohol-addicted rocker. Dr Seabrook believes that recent research indicates that while fewer people are drinking, those who are, are hitting the bottle to excess, thereby polarising society.

Martin Smith, director for the addiction treatment programme at The Priory (a London rehab centre favoured by celebrities) says: “I think there have always been people who chose to abstain for lifestyle reasons. But sadly, it hasn’t had any impact on the number of people seeking treatment for addiction. If you’re one of those people who can just take things or leave them, you are unlikely to ever knock on The Priory’s door. Of course, just because someone can abstain for a brief period doesn’t mean they don’t have a problem with addiction. I don’t think the number of celebrities having trouble with addiction has changed.”

The number of celebrities sober after a spell in rehab are, sadly, numerous. Kristin Davis, star of Sex and the City, is a recovering alcoholic, along with the television presenter Anne Robinson and the artist Damien Hirst. Big Brother presenter Davina McCall and comedian Russell Brand have had well-publicised addiction problems in the past, but are clean now.

The difference between those who resist the demon drink for lifestyle reasons and those who can’t drink because they’ve had problems in the past is highlighted by Robinson, whose high-profile addiction to alcohol forced her to stop drinking in the late 1970s.

“On the one hand, in my experience, people are drinking less,” she says. “The people I go out with of an evening quite often don’t drink. Culturally, too, as a nation we don’t drink like we used to. The circles I move in today are different from how they were when I was on Fleet Street 10 or 20 years ago.

“There are very obvious reasons for that. The culture of journalism, for example, where I used to work, has changed. Many articles are written by freelancers, who aren’t in the office, so there is no collection of people who go to the pub together after work. In wider society, too, half of the pubs have turned into coffee shops, especially in London.

“But for the Robbie Williamses of this world, those whom you may describe as a former addicts, that is a whole different story. I defy anyone to prove that figures are getting better for that.”

The socialite Tara Palmer-Tomkinson, suffered from high-profile drink and drugs problems in the past, but is now clean, and warns of the perils of partying too hard.

“The crowd I hang around with aren’t the party crowd any more,” she says. “I’ve not been to a nightclub in ages. Nowadays, I prefer dinner parties on my terrace or going out for a nice dinner. Of course, you do get people who go out and want to go crazy. I’ve never understood that mentality. Then again, I am a bit of a contol freak, perhaps it’s the Capricorn in me. Drunk people really scare me.

“But I’ve noticed that increasing numbers of people don’t drink alcohol any more – and drugs are completely out of fashion. They’re now seen as a bit seedy and unglamorous.”

Posh mocktails: even better than the real thing

The coolest non-alcoholic cocktails to be seen sipping as recommended by Davide Cade, head barman at Claridges Bar, London

Cuban Cooler

Take a highball glass and add

a sprig of mint;

one teaspoon of sugar;

15ml apple juice;

15ml lime juice.

Mix with a spoon in the glass, then add 10ml cranberry juice on top for a bit of colour and fill with crushed ice to the top of the glass. Add a wedge of lime as desired as a garnish

Very Berry Fever

Take a highball glass and add

10ml raspberry juice;

10ml blueberry juice;

10ml blackberry juice;

a teaspoon of sugar.

Mix in the glass, add crushed ice as desired and 15-20ml of lemon juice. Top the glass up with soda water.

Mix again with a spoon

Mock

Mix together in a cocktail shaker

a teaspoon of strawberry jam;

5 blackberries;

a teaspoon of sugar;

10ml lemon juice;

30ml of grapefruit juice;

30ml of pineapple juice;

a small amount of ice.

Pour into a whisky glass and garnish with a strawberry cut into three pieces.

(c) 2008 Independent, The; London (UK). Provided by ProQuest Information and Learning. All rights Reserved.

The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer

WAYNE, N.J. and EMERYVILLE, Calif., July 23 /PRNewswire-FirstCall/ — Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that The New England Journal of Medicine published results of a Phase 3 trial demonstrating that Nexavar(R) (sorafenib) tablets decreased the absolute risk of death by 31 percent in patients with unresectable hepatocellular carcinoma (HCC), or liver cancer, versus patients who received placebo. This represents a 44 percent improvement in median overall survival for patients treated with Nexavar.

Based on the strength of these data, Nexavar was approved for HCC by the European Agency for the Evaluation of Medicinal Products (EMEA) and by the U.S. Food and Drug Administration (FDA) in October and November 2007, respectively.

“Despite advances in the management of many other cancers, liver cancer has remained a treatment challenge, due to a lack of systemic therapies to extend life and limited opportunity for surgical intervention,” said Dr. Josep M. Llovet, co-principal investigator of the study and professor of research, Barcelona Clinic Liver Cancer (BCLC) Group, IDIBAPS, Liver Unit, Hospital Clinic Barcelona; director of research, HCC Program, associate professor of Medicine, Mount Sinai School of Medicine, New York. “This landmark study reflects a new systemic standard of care using Nexavar in the first-line management of liver cancer.”

“The number of lives lost to liver cancer continues to increase globally, due to the prevalence of hepatitis B and C infections,” said Jordi Bruix, co-principal investigator and director of the Barcelona Clinic Liver Cancer (BCLC) Group; senior consultant, Liver Unit, Hospital Clinic of Barcelona. “We are encouraged that there is a new treatment option available for liver cancer that has clearly demonstrated a survival benefit in this patient population.”

The international Phase 3 double-blind, placebo-controlled Sorafenib HCC Assessment Randomized Protocol (SHARP) trial evaluated 602 liver cancer patients who had no prior systemic therapy. The primary endpoints of the study included overall survival and time to symptomatic progression in patients administered Nexavar versus those who received placebo. Secondary endpoints included time to progression, disease control rate and safety.

Results were first presented at the American Society of Clinical Oncology in June 2007.

Median overall survival was 10.7 months for patients who received Nexavar compared to 7.9 months for patients who received placebo (HR=0.69; p=0.0006). There was no difference in time to symptomatic progression between patient groups, based on a patient-reported assessment questionnaire.

Median time to tumor progression was 5.5 months with Nexavar versus 2.8 months with placebo (HR=0.58; p=

“Hepatocellular cancer is the second type of cancer where Nexavar has demonstrated a meaningful clinical benefit,” said Dimitris Voliotis, MD, vice president, Nexavar Clinical Development, Bayer HealthCare Pharmaceuticals. “We are pleased that Nexavar is now available to patients suffering from liver cancer in the U.S. and Europe and we continue to work with worldwide regulatory authorities to secure approvals in other regions.”

Hepatocellular carcinoma is the most common form of liver cancer and is responsible for about 90 percent of the primary malignant liver tumors in adults. Liver cancer is the sixth most common cancer in the world and the third leading cause of cancer-related deaths globally. More than 600,000 cases of liver cancer are diagnosed worldwide each year (more than 400,000 in China, South Korea, Japan and Taiwan, 54,000 in the European Union, and 15,000 in the United States) and the incidence is increasing. In 2002, approximately 600,000 people died of liver cancer including approximately 370,000 in China, South Korea and Japan, 57,000 in the European Union, and 13,000 in the United States. (1,2)

In addition, chronic hepatitis B (HBV) and C (HCV) viral infections are the leading causes of primary liver cancer worldwide. In the Asia-Pacific region, more than eight percent of the general population is infected with HBV and between two and four percent is infected with HCV. (3,4)

Nexavar’s Differentiated Mechanism

Nexavar targets both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to target members of two classes of kinases known to be involved in both cell proliferation (growth) and angiogenesis (blood supply) — two important processes that enable cancer growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET. Preclinical models have also demonstrated that Raf/MEK/ERK has a role in HCC; therefore blocking signaling through Raf-1 may offer therapeutic benefits in HCC.

Nexavar is currently approved in more than 40 countries for liver cancer and in more than 70 countries for the treatment of patients with advanced kidney cancer. Nexavar is also being evaluated by the companies, international study groups, government agencies and individual investigators as a single agent or combination treatment in a wide range of cancers, including metastatic melanoma, lung cancer, breast cancer and as an adjuvant therapy for kidney cancer.

Important Safety Considerations For Patients Taking Nexavar

Based on the currently approved U.S. package insert for the treatment of patients with unresectable hepatocellular carcinoma, hypertension may occur early in the course of therapy and blood pressure should be monitored weekly during the first six weeks of therapy and treated as needed. Bleeding with a fatal outcome from any site was reported in 2.4% for Nexavar and 4% in placebo. The incidence of treatment-emergent cardiac ischemia/infarction was 2.7% for Nexavar vs. 1.3% for placebo. Most common adverse events reported with Nexavar in patients with unresectable HCC were diarrhea, fatigue, abdominal pain, weight loss, anorexia, nausea and hand-foot skin reaction. Grade 3/4 adverse events were 45% for Nexavar vs. 32% for placebo. Women of child-bearing potential should be advised to avoid becoming pregnant and advised against breast-feeding. In cases of any severe or persistent side effects, temporary treatment interruption, dose modification or permanent discontinuation should be considered.

For information about Nexavar including U.S. Nexavar prescribing information, visit http://www.nexavar.com/ or call 1.866.NEXAVAR (1.866.639.2827).

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R) (sorafenib) tablets, a small molecule drug. For more information about Onyx, visit the company’s website at: http://www.onyx-pharm.com/.

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals unit of Bayer HealthCare LLC, a division of Bayer AG. One of the world’s leading, innovative companies in the healthcare and medical products industry, Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the U.S., Bayer HealthCare Pharmaceuticals comprises the following business units: Women’s Healthcare, Diagnostic Imaging, Specialized Therapeutics, Hematology/Cardiology and Oncology. The company’s aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

About Bayer Schering Pharma AG, Germany

Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, General Medicine, Specialty Medicine and Women’s Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve quality of life.

Forward Looking Statements

This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer Web site at http://www.bayer.com/. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

This news release also contains “forward-looking statements” of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the results of the clinical development, safety, regulatory processes, commercialization efforts or commercial potential of Nexavar. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to Onyx’s Annual Report on Form 10-K for the year ended December 31, 2007, filed with the Securities and Exchange Commission under the heading “Risk Factors” and Onyx’s Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Healthcare Pharmaceuticals, Inc.

   (1) Ferlay J, et al., GLOBOCAN 2002.  Cancer Incidence, Morality and       Prevalence Worldwide.  IARC CancerBase No.5, Version 2.0.  IARCPress,       Lyon, 2004.  Available at: http://www-dep.iarc.fr/.  Accessed May 2008.   (2) 2005 Cancer Register System (CRS) annual report,       http://crs.cph.ntu.edu.tw/crs_c/annual.html.  Accessed May 12, 2008.   (3) World Health Organization, Fact Sheet N degree 164, October 2000.       http://www.who.int/mediacentre/factsheets/fs164/en/.  Accessed May       2008.   (4) Stanford University School of Medicine, Asian Liver Center, "FAQ About       Hepatitis B," February 2008.       http://liver.stanford.edu/Education/faq.html.  Accessed May 2008.  

Bayer HealthCare Pharmaceuticals; Onyx Pharmaceuticals, Inc.

CONTACT: Mark Bennett of Bayer HealthCare Pharmaceuticals,+1-203-314-5556; or Julie Wood of Onyx Pharmaceuticals, Inc., +1-510-597-6505;or Geoff Curtis of WeissComm Partners, +1-312-550-8138, for Bayer HealthCarePharmaceuticals and Onyx Pharmaceuticals, Inc.

Web site: http://www.nexavar.com/http://www.onyx-pharm.com/

E.R. To Reopen at Former Pascack Valley Site ; Hackensack Med Center Hiring for Oct. 1 Debut

By LINDY WASHBURN, STAFF WRITER

The emergency room at the former Pascack Valley Hospital in Westwood will open on Oct. 1, its new owners said Monday.

Hackensack University Medical Center North at Pascack Valley, as it will be called, is already hiring doctors and nurses for the new emergency department.

The sole physician on site most hours will have a robot to beam medical information to and from the department head at Hackensack University Medical Center and other sub-specialty physicians.

“It’s really happening,” said John Ferguson, Hackensack’s chief executive officer, as he led a group of local officials and reporters through the areas under renovation. “We’re tearing things down, putting things up.”

The facility’s opening date is definitely Oct. 1, he said. “I don’t accept Oct. 2.”

The emergency department is the same size 14 bays for patient care as it was under the previous owners. There will be no overnight beds for patients. Anyone requiring more advanced care or more than 12 hours of observation will have to be transferred to another hospital.

Hackensack will submit an application by month’s end for state approval to open a 120-bed community hospital on the site, Ferguson said. Despite anticipated opposition from competing hospitals and the recommendations of a governor’s commission that fewer, rather than more, hospital beds are needed in North Jersey Ferguson said he was “totally confident” the community hospital would open.

Once approved, the first beds would open in February, said Robert Kohler, a Hackensack vice president, with the rest within 2 years. Construction is expected to total $60 million.

Westwood Mayor John Birkner Jr., who joined the tour, said he was pleased with the progress.

“The whole community wants this hospital to reopen,” he said. Hackensack is donating a van to the borough of Westwood to replace one that had been used to transport senior citizens, he announced during the tour.

Hackensack is sinking $1.8 million into preparations for the free- standing emergency department, Kohler said: $800,000 for interior, “cosmetic” improvements, and $1 million to reseal the weedy parking lot and improve the entryway and roads.

The E.R. anticipates about 11,000 patient visits in its first year, with 20 percent requiring hospital admission, said Dr. Joseph Feldman, chairman of emergency medicine.

First-aid squads will be advised that patients with life- threatening emergencies, such as potential heart attacks, should be taken directly to full-service hospitals, said Lisa Iachetti, the emergency department’s director of nursing. People under the influence of drugs or alcohol, and women more than 20 weeks pregnant, also should bypass the free-standing emergency department, according to state regulations.

So far, 18 nurses and five physicians have been hired, Iachetti said. They are considered employees of Hackensack University Medical Center, Iachetti said. Hackensack is a non-union hospital, while nurses at the former Pascack Valley were members of the Health Professional and Allied Employees union. The nurses already are working in Hackensack, and will be rotated to Westwood when it opens, she said.

The free-standing E.R. will have a laboratory and imaging facilities, with radiology, CT scan and sonography. Food service will be transported from Hackensack, with vending machines on site. The medical-imaging department also will be open for outpatient visits.

***

E-mail: [email protected]

(c) 2008 Record, The; Bergen County, N.J.. Provided by ProQuest Information and Learning. All rights Reserved.

Rapist Parole Hearing Brings Bad Memories

A victim of a convicted serial rapist never wants to see him released from prison, she told the Portland Oregonian while recounting her experience.

Renee M. Smith was 17 in 1980 when Richard Gillmore allegedly broke into her home and made her his fourth victim. It wasn’t until 1986 however that police charged Gillmore with the rape of a 13-year-old girl. Once arrested, he confessed to seven earlier rapes, including that of Smith, who testified at his sentencing and has now come forward to oppose the Oregon Board of Parole and Post-Prison Supervision’s consideration of Gillmore’s case.

He’s ruined so many people’s lives. He doesn’t deserve to have a life of his own. He threw that chance away when he did what he did to all of us girls, she concluded in the Oregonian’s Wednesday exclusive.

For Hospitals and Outpatient Clinics, Finally, an Answer to Medical Claims Denials

Hospitals and outpatient clinics are in a crisis. Due to increasingly complicated, ever-changing regulatory rules governing Medicare and Medicaid billing, healthcare providers are losing revenue to denied medical claims. Since most hospitals and clinics handle billing in-house, many are drowning in denied claims and unpaid bills — until now. Millin Associates (www.millinmedical.com) — the leader in medical claims denials — has fused traditional business practices and cutting-edge technology to revolutionize the field. And a growing number of prestigious institutions are signing on — including Albert Einstein College of Medicine and the New York College of Podiatric Medicine.

In 2003, Sol Weiss acquired Millin Associates LLC (formerly Millin Medical), a 26-year old industry leader. Young, tech-savvy — and having worked in his parents’ homecare agencies — Weiss had a plan. He implemented spreadsheets allowing him to import 100,000 claims simultaneously. He then developed an innovative software program using new servers and technology — creating a web-based, simple, practice management/billing system. Millin began offering clients a 6-week turnaround (the industry standard was three months.) Additionally, all payments go directly to the facility — which clients love. Utilizing unique invoice numbers, there is a record of Millin’s efforts — and all recovery is done on a contingency basis.

Millin’s consulting arm provides CFOs with complete financial reports analyzing the source of denials, allowing them to analyze in-house processes and act on inefficiencies. Large hospitals and clinics — always conscious of the bottom line — need this transparency. Today, Millin is recommended by many leading law firms, accounting firms, and independent auditors.

Millin is a member of HFMA, CHCANYS, The Coalition of Voluntary Mental Health Agencies, Alcoholism and Substance Abuse Providers of NY State, among others. Millin is HIPAA-compliant and processes denials/current billing for Federally Qualified Health Centers (FQHC), primary care centers (Article 28), ambulatory surge centers, mental health facilities (Article 31), substance abuse facilities (Article 822), OMRDD facilities, and foster care agencies.

Meyer Futersak, head of Marketrend Media, who represents Millin, states, “Millin’s cutting-edge software, first-rate service, and range of services speaks to even the largest hospitals.” Weiss is optimistic about Millin’s potential. “We ask service providers, ‘If you’re in New York and you’re losing money, why not call us? We’re large enough to handle your claims, but small enough to provide personalized attention.'”

 For more information, contact: Marketrend Media (718) 781-0549  

SOURCE: Millin Associates

Lower Belly Fat Is Rich In Stem Cells

ASPS study finds some areas of the body have greater concentrations of stem cells

Fat removed from the lower abdomen and inner thigh through liposuction was found to be an excellent source of stem cells, with higher stem cell concentrations than other areas of the body, reports a Brazilian-based study in August’s Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS). This is the first study of its kind to examine whether fat tissues from different areas of the body vary in stem cell concentration.

“Adult stem cells, derived from our own tissues, hold strong promise for improved clinical therapies,” said J. Peter Rubin, MD, a member of the ASPS Fat Grafting Task Force who is involved in pre-clinical trial work on stem cells taken from fat. “The potential for healing and repairing injury or disease through stem cells, including conditions like breast cancer and reconstruction, heart failure, spinal injuries, diabetes and Parkinson’s disease are incredible. We may be able to more permanently and naturally get rid of pesky wrinkles or augment breasts with stem cell enriched fat in the future as well. Knowing more about the biology of stem cells will be of great value when we are ready for clinical trials in this country.”

In the study, 23 female patients having liposuction in at least four different body areas agreed to have their fat isolated for adult stem cells and analyzed to determine stem cell concentrations. The body areas that were liposuctioned were: lower abdomen, upper abdomen, inner knee, inner thigh, flank and hips.

The study results found a significant difference in stem cell concentrations in different areas of the body. A major finding was that the concentration of stem cells was greatest in the lower abdomen and inner thighs. Interestingly, stem cell concentration in the lower abdomen was five times greater than in the upper abdomen.

“The value of stem cells harvested through fat is the ready and ample supply available,” said ASPS President Richard D’Amico, MD. “Using stem cells will some day have very practical applications to the specialty of plastic surgery. That we may be able to generate new tissue or bone that can be used in many of the reconstructive and cosmetic procedures we do every day is a tremendous.”

Stem cells are unspecialized cells that have not yet developed a specific function. Not only are they capable of self renewal, stem cells can divide and produce others that become specialized cells. Scientists and doctors theorize that stem cells will be able to repair or replace damaged or diseased cells. Clinical trials researching the potential of stem cells from fat are ongoing in Europe and Asia. In the U.S., there are many investigators doing pre-clinical trial work to meet the stringent safety guidelines the FDA sets for clinical trials.

According to ASPS statistics, more than 301,000 liposuction procedures were performed in 2007.

On the Net:

ORLive Presents: Breast Reconstruction With Tissue Expansion

On July 31, 2008, at 6pm EDT, OR-Live will broadcast a breast reconstruction with tissue expansion from Albany Medical Center in Albany, New York. This procedure will be performed by Dimitri J. Koumanis, MD, Assistant Professor of Surgery, Department of Surgery, Division of Plastic Surgery, Albany Medical College and Jerome D. Chao, MD, FACS, Assistant Professor of Surgery, Chief of Division of Plastic Surgery – Department of Surgery, Division of Plastic Surgery, Albany Medical College. Dr. Koumanis and Dr. Chao will perform the tissue expansion using Veritas(R) Collagen Matrix (“Veritas”), an innovative biologic material which remodels into the tissue it is used to repair. Veritas is a tested, FDA cleared and exciting alternative to currently available synthetic and biologic meshes. Questions from healthcare professionals and the general public can be sent to Dr. Koumanis and Dr. Chao during the broadcast and the seven days following. Dr. Koumanis and Dr. Chao will address questions during this period as time permits.

Veritas Collagen Matrix, from Synovis Life Technologies, is an innovative non-cross-linked biologic material derived from bovine pericardium indicated for use as an implant for the surgical repair of soft tissue deficiencies, including abdominal and thoracic wall repair, muscle flap reinforcement, and repair of hernias. Veritas is produced through a patented process that results in an extremely biocompatible and highly acellular remodelable material. Once implanted, Veritas provides a scaffold for connective tissue protein synthesis and host tissue in-growth. The result is the seamless integration of Veritas into the surrounding host tissue.

Veritas has been used successfully in contaminated wounds and in the presence of infection as well as in other challenging situations. The U.S. Food and Drug Administration (FDA) granted Synovis the following additional indication: Veritas minimizes tissue attachment to the material when in direct contact with viscera. Veritas is the first biologic to have received this important indication from the FDA.

Veritas has been used successfully in a variety of surgical procedures including: complex abdominal wall repair, laparoscopic hiatal hernia repair, chest wall reconstruction, and breast reconstruction.

Dr. Jim Koumanis is a plastic surgeon and assistant professor of surgery at Albany Medical Center. He has extensive training from Nassau University Medical Center, Indiana University and McGill University in Montreal, Canada. He received his medical degree from the University of Western Ontario.

Dr. Koumanis specializes in microsurgery, burns and aesthetic surgery, and complex reconstructive surgery due to trauma and cancer.

Dr. Jerome Chao is a plastic surgeon and assistant professor of surgery at Albany Medical Center. He is a 1990 graduate of Harvard University, and received his medical degree from the College of Physicians and Surgeons of Columbia University. Dr. Chao trained at McGaw Medical Center of Northwestern University in Chicago, and The New York Orthopaedic Hospital of Columbia University Medical Center.

Dr. Chao specializes in aesthetic surgery, reconstructive surgeries including breast reconstruction, hand surgery, skin cancer surgery, peripheral nerve surgery, post-bariatric plastic surgery and wound healing.

Albany Medical Center is northeastern New York’s only academic health sciences center. It consists of Albany Medical College, Albany Medical Center Hospital and the Albany Medical Center Foundation, Inc. Additional information about Albany Medical Center can be found at www.amc.edu.

About Synovis Life Technologies

Synovis Life Technologies, Inc. (NASDAQ: SYNO), based in St. Paul, Minn., is a diversified medical device company engaged in developing, manufacturing, and bringing to market medical devices for the surgical treatment of disease. For additional information on Synovis Life Technologies and its businesses, visit the company’s Web site at www.synovislife.com.

View a program preview and learn more by visiting OR-Live.

VNR: www.OR-Live.com

Video-Link Available: http://www2.marketwire.com/mw/frame_mw?attachid=802168

 Contact: Alex Fraser Director of Marketing OR-Live, Inc. 860-953-2900 x 214 Email Contact

SOURCE: OR-Live, Inc.

The Modesto Bee, Calif., Dave Hill Column: Brewing Up a New Business

By David W. Hill, The Modesto Bee, Calif.

Jul. 23–You know the economy is in bad shape when coffeehouse giant Starbucks is closing 600 stores nationwide, including the two in the Northern San Joaquin Valley: one on Tully Road in Modesto and the other in Atwater. It’s all part of the strategy by the company to eliminate some underperforming stores and get a grip on slipping sales.

And it’s not just the 800-pound gorilla of the retail coffee industry that’s suffering. As the economy weakened, small independent coffeehouses also have been hard hit as consumers cut down on trips to get their favorite espresso drinks. But Perry and Camaron Keyes of Waterford weren’t deterred by the challenging conditions faced by businesses big and small these days, launching the first of what they hope will be a string of coffeehouse franchises under the Beans Coffee Co. brand. Their flagship outlet is just off the highway at 12120 Yosemite Blvd. in Waterford. It sits in the new strip shopping center on the south side of Yosemite, also known as Highway 132, just west of the IGA grocery store. They also own the Mountain Mike’s Pizza and Mountain Creamery near their coffeehouse.

Beans will feature blends from Modesto-based Clayton’s Coffee Co. Besides fresh-brewed coffees and the full-range of espresso drinks, customers can purchase whole beans. Folks also will find blended ice-coffee drinks, fresh fruit smoothies, teas, pastries, salads, veggie cups, wraps and more. Wraps are the signature items on the menu, with seven kinds available daily, such as the chicken club.

The coffeehouse offers all the typical amenities, comfortable chairs to lounge in, soothing music and warm interior colors. Beans also provides free WiFi Internet access — sit, sip and surf. There’s a patio for those who want to sit outside, and a drive-through.

Hours are 6 a.m. to 8 p.m. Monday through Thursday, 6 a.m. to 9 p.m. Friday, 7 a.m. to 9 p.m. Saturday and 7 a.m. to 6 p.m. Sunday. For more information, call 874-3083. While it might seem like a strange time to launch a coffeehouse, the Keyeses think Beans has the right blend of ingredients to be successful — not too weak, not too strong, made to order.

Elsewhere on the Business Beat:

Another entrepreneur who thinks now’s a good time start a small business is Susan Johnston, who recently kicked open the doors to her Bonnie J shoe boutique in downtown Modesto.

Johnston, a veteran of the retail industry, is stocking her shop at 1020 J St. with designer shoes of all sizes, shapes and styles, from flip flops to formal heels. Named for late mother Bonnie J. Brocco, the shop carries such brands as Betsey Johnson, Sam Edelman, Calvin Klein, Yellow Box, Jeffrey Campbell and Donald J. Pliner.

She’s also carries designer handbags and fashion jewelry. Johnston can special order those special pumps directly from shoe designers. The shop hosts private shoe parties for those who want that special shopping experience. Women who want to give their husbands and friends some gift ideas also can set up wish lists with their shoe and accessory favorites — now if we could only remember those important dates.

Hours are 11 a.m. to 5:30 p.m. Tuesday through Saturday. For more information, call 521-2700. See you there. I’ll be the guy carrying a wish list and calendar.

Have an item for Business Beat? Send it to David W. Hill, The Modesto Bee, P.O. Box 5256, Modesto 95352; or [email protected].

—–

To see more of The Modesto Bee, or to subscribe to the newspaper, go to http://www.modbee.com/.

Copyright (c) 2008, The Modesto Bee, Calif.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

NASDAQ-NMS:SBUX,

Strategic Buyers, Investment Groups Vie for Opportunities in Managed Care, More at iiBIG Forum

iiBIG presents the Investment and M&A Opportunities in Managed Care conference, scheduled for November 17-18, 2008 in New York City.

In recent years, health care industry buyers making acquisitions for strategic reasons have found themselves in bidding wars with investment groups — and health insurers themselves have become willing to take on greater levels of debt. MCOs are buying up healthcare operations big and small to expand into new geographies, diversify product lines, and jump-start specialty operations. In an environment where managed care plans are struggling with costs, that trend is expected to intensify throughout this year and 2009.

Preliminary Speaking Faculty Includes:

 --  Steve Wiggins, Managing Director, Essex Woodlands Health Ventures     (Founder and former Chairman of the Board & Chief Executive Officer, Oxford     Health Plans)      --  Bradley P. Casemore, Chief Operating Officer, Venture Behavioral     Health      --  Benjamin Edmands, Managing Director, CCMP Capital      --  Craig D. Frances, MD, Managing Director, Summit Partners      --  Bruce Merlin Fried, Partner, Sonnenschein, Nath & Rosenthall, LLP      --  Chris Hunter, Senior VP& Treasurer, BlueCross BlueShield of Tennessee      --  Gary Jacobs, Senior VP, Corporate Development, Universal American      --  Carl McDonald, Executive Director, Managed Care Analyst, Oppenheimer      --  Court H. Houseworth, Managing Director, Cain Brothers      --  Daniel C. Lyons, MD, President & CEO, Veridign Health Solutions      --  Michael O'Neil, Senior VP, Strategy and Development, HealthSpring      --  Dan Paquin, Chief Operating Officer, CareSource Management Group      --  Michael Quilty, Chief Executive Officer, Matrix Medical Network      --  Bill Suddath, Managing Director, Healthcare Services Investment     Banking, Robert W. Baird & Co.      --  Lambert van der Walde, Capital Markets Advisor to the Administrator,     Center for Medicaid & Medicare Services, U.S. Department of Health & Human     Services      --  Ned Villers, Principal, Water Street Healthcare Partners      --  W. Paul Wallace, Senior VP, Corporate Development, Healthways      --  Nathaniel M. Zilkha, Principal, Healthcare Investing Group, Kohlberg     Kravis Roberts & Co.      

 CONFERENCE UPDATES AND INQUIRIES: Visit: http://www.iibig.com/F0807 Phone: 212-300-2523 E-mail: [email protected] 

ABOUT iiBIG

iiBIG (International Institute for Business Information & Growth) is an unbiased, independent company dedicated to organizing business-to-business conferences and seminars for senior-level business executives. Our events focus on the most pressing and timely issues facing decision-makers in today’s global economy. For more information, visit: http://www.iibig.com.

 Ria Lubis VP, Marketing iiBIG Phone: 212-300-2523 E-mail: Email Contacthttp://www.iibig.com/F0807

SOURCE: iiBIG

NJHA Receives Planning Grant From RWJF for Regional Market Quality Project

PRINCETON, N.J., July 23 /PRNewswire-USNewswire/ — The New Jersey Hospital Association’s Institute for Quality and Patient Safety has received a planning grant for $199,502 from the Robert Wood Johnson Foundation (RWJF) to develop a proposal for improving the quality of healthcare in New Jersey.

The grant will help determine over the next six months whether New Jersey can be represented in RWJF’s Aligning Forces for Quality initiative, which is focused on lifting the overall quality of healthcare in targeted communities, reducing racial and ethnic disparities, and providing models of national healthcare reform for other parts of the country. The Foundation launched the Aligning Forces initiative last month. Materials about the Aligning Forces initiative can be found at http://www.rwjf.org/.

NJHA’s Institute for Quality and Patient Safety will be the leadership organization for this project. NJHA’s Aline Homes, senior vice president of clinical affairs, will serve as project director, and Peter A. Gross, MD, senior vice president and chief medical officer for Hackensack University Medical Center, will act as project co-director.

“This is an excellent opportunity for us to participate in a project that could have an enormous positive effect on the quality of healthcare delivered to patients. There will be a number of key players involved in this initiative including the Department of Health and Senior Services, the Department of Banking and Insurance, The Rutgers Center for State Health Policy, The Medical Society of New Jersey and The New Jersey State Nurses Association,” stated Holmes.

This group will meet on a regular basis for the next six months to develop a statewide plan for quality improvement that will be submitted to RWJF in December.

Based in Princeton, NJHA has been providing its 108 members with advocacy, information, research and education since 1918.

New Jersey Hospital Association

CONTACT: Kerry McKean Kelly, +1-609-275-4069, or Aline Holmes,+1-609-275-4157, both of New Jersey Hospital Association

Web Site: http://www.rwjf.org/

TheraDoc(R) Real-Time Surveillance and Clinical Decision Support Technologies Adopted By Two Leading Health Systems

BayCare Health System in the Tampa Bay region and PeaceHealth healthcare system, headquartered in Bellevue, Wash., have selected real-time electronic surveillance and expert clinical decision support systems provided by TheraDoc, Inc., a clinical informatics company headquartered in Salt Lake City, UT. TheraDoc’s interoperable, patented Expert System Platform(R) (ESP) is a standards-based, scalable solution that provides hospitals with real-time surveillance, management, prevention and reporting of patient safety problems such as hospital-acquired infections (HAI) and adverse drug events (ADE).

BayCare’s nine-hospital system has licensed TheraDoc’s ESP and a suite of Knowledge Modules that includes the Infection Control Assistant(R), Antibiotic Assistant(R) and ADE Assistant(R). With a long-standing focus on reducing infections throughout its healthcare system, BayCare sought a standardized process for HAI surveillance, infection control, antimicrobial stewardship, adverse drug event prevention and medication safety. TheraDoc’s real-time surveillance and reporting capabilities, infection identification, and ability to integrate other hospital data without significant customization were evaluated by BayCare as their preferred solution to enhancing the quality and efficiency of care.

According to Dr. Denise Remus, Ph.D., RN, and Chief Quality Officer for BayCare Health System, “TheraDoc technology brings many benefits and efficiencies to enhancing infection control monitoring and reporting, providing logical alerts, and reducing paperwork – all of which will help us improve patient care. The technology’s user interface was easy to maneuver and understand, and we saw real value and many resources in their solutions.”

“As the largest non-profit healthcare system in the Tampa Bay area,” added Remus, “BayCare sees TheraDoc technology as another tool and resource to improve the quality of care we provide to our community.”

PeaceHealth’s six hospitals in the Northwest will also utilize TheraDoc’s ESP and its complete suite of Knowledge Modules: Infection Control Assistant, Antibiotic Assistant, ADE Assistant and Clinical Alerts Assistant(R), with immediate implementation slated for July 2008. In 2003, the health system first implemented TheraDoc’s ESP, Antibiotic Assistant, ADE Assistant and Clinical Alerts Assistant to enhance antimicrobial stewardship and patient care at two of its six hospitals. The system-wide implementation of the Infection Control Assistant will allow PeaceHealth to take advantage of TheraDoc’s automated, comprehensive, work-flow centric infection surveillance and reporting technologies, improving surveillance efficiency and productivity, as well as reducing the paperwork of infection control practitioners.

“TheraDoc’s real-time infection surveillance software is the logical next step toward empowering infection prevention and control,” said Jette Hogenmiller PhD, ARNP, CDE, and System Quality Improvement Manger for Infection Prevention at PeaceHealth. “Its efficiencies in data surveillance, workflow enhancement, ease of use and, most importantly, real-time reporting capabilities, will enable us to stay ahead of the curve with infection prevention as well as support our commitment to excellence in patient care.”

TheraDoc president and CEO, Stan Pestotnik said, “We are delighted to work with both PeaceHealth and BayCare Health Systems in advancing their patient safety and quality initiatives through our Clinical Intelligence(TM) system. TheraDoc has a non-negotiable adherence to healthcare industry standards and best practice solutions that improve patient safety and provide measureable results and improved financial outcomes.”

Pestotnik added that the ability of TheraDoc technology to identify and prevent infections and support clinical decision making is of particular importance given new regulations imposed by the Centers for Medicare and Medicaid Services (CMS) starting October 1, 2008. Under these new regulations, hospitals will no longer be reimbursed for costs related to preventable conditions, including HAIs and some medical errors.

Founded in 1999, TheraDoc technology has been licensed by more than 200 hospitals in 30 states, plus the District of Columbia. Among these are Johns Hopkins, University of Pittsburgh Medical Center (UPMC) Mayo Clinic-Florida, University of Pennsylvania Health System (UPHS), Chicago Northwestern Memorial Hospital, Emory Healthcare in Atlanta and the National Institutes of Health (NIH) Clinical Center. Hospitals using TheraDoc technology range from community hospitals with under 100 beds to integrated delivery networks (IDNs) with more than 3,700 beds, academic and VA medical centers, as well as children’s and oncology specialty hospitals.

About TheraDoc, Inc.

TheraDoc is a clinical informatics company dedicated to improving the quality, efficiency and safety of patient care through enhanced clinical decision making. It provides innovative, best-in-class solutions that improve clinical and financial outcomes at a range of provider and payer organizations, including some of the most-respected healthcare institutions in the country. With clinical transparency, TheraDoc’s technologies seamlessly place mission-critical knowledge at the clinician’s fingertips, helping them to confidently manage multiple processes of care across multiple conditions and diseases. The company’s strict adherence to medical informatics standards enables connectivity and interoperability with any hospital’s disparate health information systems.

Founded in 1999, TheraDoc designs, develops, and supports a suite of clinical decision support technologies, all of which utilize a proprietary inference engine that enables its real-time capabilities. TheraDoc’s founders and core medical informatics team are internationally recognized for their pioneering work in medical expert systems. Their experience in clinical decision support design and development spans two decades. On the Net: www.theradoc.com.

About BayCare Health System

BayCare is a family of health care providers consisting of the nine leading not-for-profit hospitals in the Tampa Bay region. With 17,000 employees and other health care services, BayCare is the largest, community-based health system in the region. BayCare’s nine hospitals are: Mease Countryside, Mease Dunedin, Morton Plant, Morton Plant North Bay, St. Anthony’s, St. Joseph’s, St. Joseph’s Children’s, St. Joseph’s Women’s and South Florida Baptist. On the web: www.baycare.org.

About PeaceHealth

PeaceHealth is a Bellevue, WA-based not-for-profit healthcare system with hospitals and medical centers in Alaska, Washington and Oregon that serve more than 57,000 patients annually. Sponsored by the Sisters of St. Joseph of Peace, PeaceHealth has provided exceptional medicine and compassionate care to Northwest communities for more than a century. PeaceHealth annually receives national recognition for innovations in patient-centered care, patient safety and healthcare technology. PeaceHealth is frequently named as one of the region’s best employers. For more information, visit www.peacehealth.org.

Mercy Health Plans Announces New Name for Their Medicare Advantage Plans: Mercy Medicare Advantage

ST. LOUIS, July 23 /PRNewswire/ — Mercy Health Plans, the St. Louis-based health benefits management company founded in 1994 by the Sisters of Mercy Health System, has announced it has changed the name of its Medicare Advantage plans to: Mercy MedicareAdvantage. The plans, which serve Medicare members in St. Louis, Illinois and Southwest Missouri, previously were offered using the names PremierPlus, PremierPlus Options, St. John’s PremierPlus and St. John’s PremierPlus Options.

In the Springfield, Mo., area, the plan is now known as Mercy MedicareAdvantage, in partnership with St. John’s. Mercy Health Plans and St. John’s Health System, a system of hospitals and physician clinics also sponsored by the Sisters of Mercy Health System, have partnered for more than 10 years to serve Medicare enrollees in the Springfield areas.

Mercy Health Plans also markets its Medicare Advantage plans in Northwest and Central Arkansas. These plans were introduced in 2007 with the Mercy MedicareAdvantage plan name.

Medicare Advantage plans are benefit plans that serve as a replacement to Medicare coverage. The plans are available to persons entitled to Medicare Part A and enrolled in Part B by age or disability living in the service area.

Mercy Health Plans has contracts with the Centers for Medicaid & Medicare Services (CMS) to offer these plans to Medicare enrollees. Mercy’s Medicare Advantage Plans include HMO and PPO plans with comprehensive benefits, many value-added programs, and are available with or without prescription drug coverage (Medicare Part D).

According to the Consumer Assessment of Health Plans Survey, Mercy’s plans consistently top the national average and are recognized by their members for their achievements in health plan overall, health care overall and customer service.

Mercy Health Plans

CONTACT: Marc Hamilton of Mercy Health Plans +1-314-214-8182,[email protected]

Web site: http://www.mercyhealthplans.com/

Teen Health Centers Promote Education

By David Harrison, The Roanoke Times, Va.

Jul. 23–Suppose you’re a high school student in Roanoke whose family has no health insurance and who doesn’t have a family doctor. Where do you go if you need medical help?

For the past 16 years that place has been the teen health centers, located at Patrick Henry High School, William Fleming High School and the Hurt Park Community Center.

The centers offer sports physicals, school physicals, treatment for minor injuries and illnesses, immunizations, family planning education, contraception and, starting last year, mental health counseling for those ages 10 to 19.

It’s a valuable service. And Ken Mundy, executive director of the Roanoke Adolescent Health Partnership, would like to see it expand.

“Education and prevention is our goal,” he said. “We’re dealing with obesity, mental health, sexually transmitted disease, family planning issues. All of those we treat but we also try to educate.”

Of the more than 3,000 adolescents served last year at the centers, most were from Roanoke. But a sizable number came from Salem, Vinton, Roanoke County and Bedford County.

Starting next year, Mundy said, the partnership will try to send information home with Roanoke County students to broaden the centers’ reach. In the past, only city students were sent home with information about the centers.

Mostly, however, patients hear about them through word of mouth. Despite taking a relatively low profile, the partnership’s educational mission has shown some impressive results.

For instance, roughly 15 percent of the pregnancy tests done at the centers turn out to be positive. But among patients who have spoken with staffers about family planning, the rate of positive pregnancy tests falls to 1 percent, Mundy said.

The partnership is independent of the school system but works closely with school health officials, city officials and the health department. Students younger than 18 need parental permission to visit the centers.

“We don’t provide transportation but we’ve found that if teens really want to get there they find a way,” said Brooks Michael, a member of the Roanoke Adolescent Health Partnership Board of Directors.

If patients have health insurance, the partnership will bill their insurance provider but about 28 percent of patients don’t have insurance and about 25 percent don’t have a family doctor, Mundy said.

“We’re their only point of contact for health care,” he said. “We don’t want to be that. We prefer that they have a family doctor and they have regular medical care.”

The partnership also moved into a new facility at the recently completed PH last year. Until then, the school’s health center was in a trailer on school grounds.

At Fleming, the center will stay in a trailer next year while a new high school is under construction.

“This time next year we should be getting ready to open it,” Mundy said.

Mundy said the partnership has talked about possibly opening a new branch to relieve pressure on the Hurt Park teen health center, the busiest of the three.

While the high school-based centers are closed for the summer, the Hurt Park center is open 8 a.m. to 5 p.m. weekdays in the summer.

Many of the patients from outside the city visit the Hurt Park center, as do some Roanoke high school students who perhaps don’t want to be seen going into one of the other teen health centers on the two campuses, Mundy said.

—–

To see more of The Roanoke Times, or to subscribe to the newspaper, go to http://www.roanoke.com/.

Copyright (c) 2008, The Roanoke Times, Va.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Tri-Town Hospital Names Replacement CEO

By The Daily Star, Oneonta, N.Y.

Jul. 23–Tri-Town Regional Hospital in Sidney has a new chief executive officer and medical director.

Dr. Marianne Soden was recently hired to take over as CEO from Bruce Wilhelm, who announced last month that he was appointed vice president of human resources at Bassett Healthcare in Cooperstown.

Bassett opened Tri-Town Regional Hospital in February. The facility is at the site of The Hospital in Sidney, which closed in July 2005, and offers around-the-clock emergency care, as well as laboratory and radiology services.

“The first five months of operation for the new hospital have been even more successful than anticipated, with patient volumes exceeding our projections,” Wilhelm said in a media release from Bassett.

“More importantly,” he continued, “we’ve been able to provide lifesaving care to people who previously had to travel long distances to an emergency department.

“Dr. Soden has the professional experience and background necessary to take the hospital’s services to the next level, and I look forward to working with her in my capacity as head of the human resource division at Bassett,” he added.

Soden completed her undergraduate degree at Binghamton University. She received her medical degree from Michigan State University and fulfilled her internal medicine residency requirements at Tulane University Medical Center in New Orleans and United Health Services in Johnson City.

She is also an associate professor of medicine at Upstate Medical Center in Syracuse. Her age and residence were not given in the release.

“I am looking forward to becoming a member of the Tri-Town community,” Soden said in the release. “I especially look forward to working with the people who live here and the board of trustees to create a vision for the hospital and its services going forward. I fully understand the challenges the region has faced and since overcome.”

She continued, “The opportunity to guide the delivery and growth of health-care services to help meet local needs is one I very much look forward to.”

Soden will also see patients at Bassett Healthcare — Sidney Primary Care and serve as the health center’s medical director.

—–

To see more of The Daily Star, or to subscribe to the newspaper, go to http://www.thedailystar.com.

Copyright (c) 2008, The Daily Star, Oneonta, N.Y.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Hospital Shows Off Pavilion: Unit Built for Surgical Care, Emergencies

By Lindell Kay, The Daily News, Jacksonville, N.C.

Jul. 23–Whether a patient is in need of emergency care or going in for minor outpatient surgery, the new addition to Onslow Memorial Hospital should help ease the pain and the wait.

The new $40 million Emergency Services and Surgical Pavilion — a convergence of modern architectural design and modern medicine — was built in about five years without a single taxpayer dollar.

The public will get a chance on Thursday from 5 to 7 p.m. to tour the new facility, but elected officials and VIPs got a sneak peak Tuesday afternoon.

N.C. Lt. Gov. Bev Perdue toured the facility and spoke at the opening ceremony.

“There was a time when critics said we couldn’t have sophisticated, comprehensive medical care in Southeastern North Carolina,” she said. “We showed them wrong one more time.”

Perdue — director of geriatric care at Craven Regional Medical center early in her career — said OMH has managed to create a “caring and 21st century medical facility.”

The new pavilion’s wide hallways and spacious operating rooms — all freshly painted in calming colors like soft white and beige — are lit brilliantly and economically with skylights.

The new building has four operating rooms designed to keep cords and as many other objects as possible off the floors. Lights and booms holding other equipment are suspended from the ceiling. An integrated system of screens mounted on the walls will allow doctors to see diagnostic images of the patients.

Other areas include special examination rooms for obstetrics and gynecology and sexual assaults; a minor procedures room for stitches and setting bones; a decontamination room for removal of biological or chemical contaminants; an isolation room; and a secure room for jail inmates.

Each operating room is equipped with intergraded video systems allowing monitoring of operations and well lit by large, bright surgical lamps that give off light, but no heat.

Within a few steps, hospital staff can take a patient from the front door of the ER to a trauma bed to Radiology.

“It is a dream come true,” said Dr. Ed Piper, the president and chief of staff of OMH.

Piper said he is extremely excited about the new facility, and pleased it was paid for without “one taxpayer penny.” But the next phase — a patient tower — will be more than the hospital can afford on its own.

“It will be a time for the community to see a cause beyond ourselves,” he said during the opening ceremony.

The new pavilion is the first major construction at the hospital in more than 30 years.

“This is the most significant construction since 1975,” said Dr. Ed Piper, president and chief of staff at the hospital. He said the 1975 expansion cost $6 million while the latest addition cost $40 plus.

He said the hospital will now be able to take care of patients who were not being treated before.

“This new ER will drastically cut down on patients leaving without being seen,” he said. “The people of Onslow County deserve the best and they’re getting the best.”

ER patients will be routed by triage staff to either the minor emergency care section or another treatment area for more severe cases. A separate observation section has been created for patients who may be or likely will be admitted. Those patients can be moved to the observation area for up to 23 hours during the transition or while a determination is being made, freeing up emergency treatment rooms for others, hospital staff said.

Hospital officials say the new emergency room means state-of-the-art emergency care, shorter wait times for patients, enhanced facilities for triage and trauma care, and with more than double the space of the current ER patient comfort and privacy will be dramatically increased.

The surgical pavilion will offer state-of-the-art surgical care, more room to accommodate the latest technology, a comfortable waiting area for family, the connivance of having both pre-op and post-op care in one location, and a drive-up entrance for outpatients.

State Sen. Harry Brown, R-Onslow, said he sat on the hospital authority several years ago.

“This is huge,” he told The Daily News. “Not just for Onslow, but for the whole region. This prepares Jacksonville to take the next step in becoming a key player in North Carolina.”

Dr. Lennox Williams, OMH chief of staff, told the crowd of 200, according to an unofficial hospital staff estimate, that the new facility will help the medical workers at OMH fulfill their Biblical mandate of treating other people the way they expected to be treated.

“After all, we will all be patients one day,” he said.

Contact crime reporter Lindell Kay at [email protected] or 910-554-8534. Read Lindell’s blog at http://onslowcrime.encblogs.com.

—–

To see more of The Daily News, or to subscribe to the newspaper, go to http://www.jacksonvilledailynews.com.

Copyright (c) 2008, The Daily News, Jacksonville, N.C.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Duluth Physician Gets Court Victory in Sex Assualt Trial

By Mark Stodghill, Duluth News-Tribune, Minn.

Jul. 23–In a setback for the prosecution, the testimony of five women who allege that a Duluth physician touched them inappropriately will not be allowed as evidence when he stands trial on a charge of sexually assaulting another female patient, a judge has ruled.

Dr. Javier De La Garza, 52, a gastroenterologist with St. Luke’s hospital, is charged with third-degree sexual assault, a felony. He is accused of having sexual intercourse with a patient without her consent on her parents’ boat while docked at Barker’s Island Marina in September 2006. According to the complaint against De La Garza, the patient was giving him a tour of the boat when he suggested giving her an exam. They went into the boat’s cabin area, where the assault occurred, the complaint said.

The Douglas County District Attorney’s Office had sought to admit testimony from the alleged victim and five other female patients of the defendant, who accused him of touching them inappropriately in a sexual manner while they were being treated by him at his office or in the hospital.

The other women’s testimony was presented during hearings in Douglas County Circuit Court in February and May. De La Garza has not been charged with sexually assaulting any of the other women. Four of the women have brought civil lawsuits against the doctor claiming he engaged in harmful, offensive and illegal sexual contact with them with no reasonable medical purpose. They allege they suffered and continue to suffer physical pain, humiliation, mental anguish, anxiety and emotional distress.

In an order filed Thursday, Douglas County Circuit Judge Michael Lucci found that the relevance of the other women’s testimony “does not measure up to any level near that of the danger of unfair prejudice that would result from its admission. Furthermore, the potential for undue delay, confusion of the issues and misleading of the jury resulting from its admission far outweighs its relevance and probative value.”

Assistant Douglas County District Attorney James Boughner said Tuesday that his office would discuss the case with the criminal appeal unit of the state attorney general’s office before deciding whether to petition the Wisconsin Court of Appeals for review, which is discretionary.

Richard Gondik, the Superior defense attorney who represents De La Garza, couldn’t be reached for comment Tuesday.

The trial is scheduled to begin Aug. 11.

Boughner argued in his motion to include the other women’s testimony that the alleged acts took place during the same time frame as the charged assault, in similar, secluded exam sites and under similar circumstances: taking advantage of a patient while claiming to provide medical services. He said the alleged past acts show De La Garza had a pattern of using his position to receive sexual gratification when examining women alone.

Lucci granted Boughner’s motion to admit into evidence at trial other incidents of alleged sexual contact with the one woman he is criminally charged with sexually assaulting.

De La Garza has practiced at St. Luke’s since 2004. A gastroenterologist is a physician who specializes in the diagnosis and treatment of gastrointestinal tract disorders. He reached an agreement with the Minnesota Board of Medical Practice on Sept. 26 to stop practicing medicine while the board investigates complaints against him.

In an unrelated matter in St. Louis County District Court in Duluth, the doctor is facing a charge of reckless discharge of a firearm within a municipality, fleeing a police officer in a motor vehicle and two counts of driving while under the influence of alcohol after a Nov. 30 incident that started as a domestic disturbance at his Congdon Park home.

MARK STODGHILL covers public safety and courts. He can be reached weekdays at (218) 723-5333 or by e-mail at mstodghill@duluthnews. com.

—–

To see more of the Duluth News-Tribune, or to subscribe to the newspaper, go to http://www.DuluthSuperior.com.

Copyright (c) 2008, Duluth News-Tribune, Minn.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)

SAN FRANCISCO, July 23 /PRNewswire/ — InCode BioPharmaceutics, Inc., an emerging biopharmaceutical company, today announced preclinical test results demonstrating the utility of their lead drug candidate rC3-1 for the treatment of the rare chronic blood disorder paroxysmal nocturnal hemoglobinuria (PNH). The complete results will be presented at the XXII International Complement Workshop in Basel, Switzerland, September 28, 2008.

The only treatment currently available for PNH patients is an anti-C5 antibody Soliris(TM) (eculizumab) sold by Alexion Pharmaceuticals, Inc.

rC3-1 promotes the enzymatic partial depletion of C3, the hub of the complement cascade. Complement protein C3 is the master regulator of complement protein C5 that mediates cell damage in PNH patients. The reduction of C3 has been shown to reduce PNH cell destruction.

PNH is a rare debilitating and life-threading disease. PNH is an acquired genetic blood disorder in which patients’ red blood cells are destroyed by complement, a component of the body’s immune system. PNH patients have a sub-population of red blood cells (PNH cells) that are susceptible to immune complement-mediated destruction. In this study, PNH cells from patients remained intact in blood serum treated with rC3-1 when compared to non-treated serums.

“rC3-1 appears to be a promising new treatment alternative with several benefits over the existing treatment,” Commented Bill St. John CEO of InCode. “The unique action of rC3-1, offers patients the potential for more convenient self-administered dosing and physicians’ a more cost effective and flexible treatment option.”

InCode is planning PNH clinical trials testing rC3-1. These trials will provide a foundation for series of subsequent clinical trials addressing macular degeneration, asthma and other autoimmune and inflammatory disease indications.

InCode BioParmaceutics, Inc. is an emerging biotechnology company that is developing a new class of recombinant proteins for the controlled depletion of complement protein C3. The therapeutic potential for C3 depletion has been demonstrated in Macular Degeneration, Asthma, Rheumatoid Arthritis, and autoimmune and inflammatory diseases. C3 depletion has also been demonstrated as a useful adjuvant to surgery, transplantation and cancer therapy. InCode is pursuing a progressive clinical development plan focused on proof of concept trials.

InCode BioPharmaceutics, Inc.

CONTACT: William St. John, President and CEO of InCode BioPharmaceutics,Inc., +1-808-268-9803, [email protected]

Web site: http://www.incodebp.com/

FDA Announces Salmonella Warning for Jalapenos

By Stacey Eidson, The Bradenton Herald, Fla.

Jul. 22–Just days after the U.S. Food and Drug Administration announced tomatoes were safe to enjoy again, federal health officials are now warning consumers not to eat fresh jalapeno peppers.

A jalapeno pepper from a small Texas-based produce distribution center tested positive as a “genetic match” to the particular salmonella strain, called Saintpaul, associated with the current nationwide outbreak, according to the FDA.

The company, Agricola Zaragoza Inc. of McAllen, Texas, has voluntarily recalled all of its jalapeno peppers, which originated from a farm in Mexico.

But the connection between the peppers tested in Texas and the largest outbreak of food-borne illness on record in the past decade was enough for the FDA to tell consumers to avoid eating fresh jalapenos.

“Currently, the warning is nationwide for all fresh jalapenos and products made from fresh jalapenos. That does not include processed products,” Dr. David Acheson, associate commissioner for foods for the FDA, said during Monday’s news conference. “The reason for that is, we do not know the exact source of this contamination.”

Acheson described the discovery at the Texas distribution center as a “huge break” in the nationwide salmonella investigation.

To date, more than 1,200 cases in 43 states have been reported in the salmonella outbreak that began in mid-April, according to Dr. Robert Tauxe, deputy director of the Division of Foodborne, Bacterial and Mycotic Diseases at the Centers for Disease Control.

There have been two associated deaths and approximately 229 people hospitalized as a result of the salmonella contamination, according to the CDC.

Boni Caro, one of the owners of mi Pueblo restaurants in Manatee and Sarasota counties, said his businesses will avoid using any fresh jalapenos until the FDA lifts its warning.

“Right now, unfortunately, we have to use canned jalapenos to make our salsa,” Caro said. “It is hard for us because we are a Mexican restaurant, but it is not going to stop business. We are just waiting to see what happens.”

Caro said it is frustrating because just a few weeks ago the restaurants had to avoid using certain tomatoes because of the FDA’s previous warning.

“The same thing happened when the tomato scare was going on,” Caro said. “And we proudly use tomatoes from Florida but we had to stop using tomatoes for a couple of weeks just until everything got cleared up. I just hope they will figure it out pretty soon.”

Shannon Patten, a spokeswoman for Publix, said she received a statement from the FDA late Monday saying the grocery chain is not affected by the pepper recall. But the federal government is still advising consumers to avoid eating any fresh jalapenos.

The FDA intends to narrow its investigation of jalapenos as quickly as possible, but the public’s safety must be the top priority, Acheson said.

“This is not about punishing anybody,” he said. “It’s about protecting public health.”

Liz Compton, spokeswoman for the Florida Department of Agriculture, said the state’s tomato industry is still reeling from the FDA’s expired warning about tomatoes.

“Fortunately, we don’t have a large jalapeno industry that will be impacted by this,” she said. “And certainly we are glad that they found a positive sample that might help find the exact source because tomato growers are not rebounding right now. There are still concerns in the public.”

“We would certainly be glad if they can figure this out and be able to declare that tomatoes were never involved,” she added. “Because there is still a dark cloud over tomatoes.”

Gary Reeder, a tomato grower with West Coast Tomato, said Florida tomatoes should have never been linked to the salmonella outbreak.

“I’m very angry that the FDA has caused all these problems for us with no substantiation from Day 1,” Reeder said. “They still have not found one case of salmonella poisoning in any tomatoes coming from Florida. Not one.”

—–

To see more of The Bradenton Herald or to subscribe to the newspaper, go to http://www.bradenton.com.

Copyright (c) 2008, The Bradenton Herald, Fla.

Distributed by McClatchy-Tribune Information Services.

For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

First-of-a-Kind Technology to Help Doctors Care for Premature Babies

IBM (NYSE: IBM) and the University of Ontario Institute of Technology (UOIT) announced today a first-of-a-kind research project to help doctors detect subtle changes in the condition of critically ill premature babies.

The project will see a group of internationally recognized researchers, led by Dr. Carolyn McGregor, a UOIT associate professor and Canada Research Chair in Health Informatics, use advanced stream computing software developed by IBM Research to work toward greatly enhancing the decision-making capabilities of doctors. The software ingests a constant stream of biomedical data, such as heart rate and respiration, along with environmental data gathered from advanced sensors and more traditional monitoring equipment on and around the babies.

The researchers will also use the software to apply findings from Dr. McGregor’s body of research to help make “sense” of the data and, in near-real-time, feed back the resulting analysis to health-care professionals so they can predict potential changes in an infant’s condition with greater accuracy and intervene more quickly.

Physicians in neonatal intensive care units (NICU) at Toronto’s Hospital for Sick Children and two other international hospitals are participating in the study.

Monitoring “preemies” as a patient group is especially important as certain life-threatening conditions such as infection can be detected up to 24 hours in advance by observing changes in physiological data streams.

The type of information that will come out of the research project is not available today. Currently, physicians monitoring preemies rely on a paper-based process that involves manually looking at the readings from various monitors and getting feedback from the nurses providing care.

“This research has the potential to greatly impact neonatal care through reduced mortality and morbidity rates and overall health-care costs,” said Dr. McGregor. “By merging our research and technology, we are able to collect more detailed patient data in a systematic manner, do online health analysis and decision support, and get advanced early warning of emerging patterns that could predict a medical event.”

When fully developed, IBM’s software will be capable of processing the 512 readings per second generated by some of these medical devices, and UOIT researchers will further test and develop its ability to analyze these vast quantities of data in real time.

Initially researchers will use NICU medical devices in UOIT’s state-of-the-art Health Informatics Laboratory to test IBM’s software using simulated patient mirroring data. Then the software will be tested using de-identified actual patient data. The de-identified data is recorded in a way that enables researchers to alter some variables, play it back and run simulations for further study.

IBM awarded Dr. McGregor access to the prototype software patented by researchers at its T.J. Watson research facility in New York under its First-of-a-Kind program, which is designed to accelerate the delivery of innovative technologies to the market and link IBM’s research work to real world problems.

“Right now, there is an enormous amount of critical data produced by machines monitoring patients,” said Don Aldridge, business executive for IBM research and life science. “That creates a challenge. The ability to quickly analyze that data and make informed decisions will help improve the overall quality of health care.”

About UOIT

For more information on UOIT, visit www.uoit.ca.

 Media contacts  For IBM: Leslie Plant IBM Media Relations Direct: (416) 478-9840 Mobile: (416) 526-5647 [email protected]  For UOIT Tony Doyle Media and Communications Direct: 905.721.8668 ext. 2209 [email protected]

SOURCE: IBM

Saudi Author Scandalizes the Muslim World

CHICAGO _ It’s not clear if Rajaa Alsanea’s first novel, “Girls of Riyadh,” was banned in Saudi Arabia because it became a Middle East best seller or if it became a best seller because it was banned.

Either way, it was a surprise for Alsanea, a soft-spoken 26-year-old Saudi who is studying dentistry at the University of Illinois at Chicago.

She wrote the book, which follows the lives of four upper-class young Saudi women who struggle to find love in a restrictive society, in her spare time. She said she hoped that by holding a mirror up to Saudi society, she could in some small way “improve” that society.

What she didn’t anticipate was 1,000 e-mails a day _ vilifying her, praising her, asking for her advice on matters of the heart or for her hand in marriage.

“It was a magical experience,” she said. “Something like this had never happened to an author in the Arab world. It changed my life overnight.”

“Girls of Riyadh” has been translated into 20 languages. The U.S. hardcover edition was published last year. The paperback came out last month. Royalties in Arab countries are minimal, but Alsanea has made about $500,000 from sales in Europe and America, she said.

In this country, the book has been promoted as a kind of “Sex and the City,” Saudi-style. It isn’t, unless you consider the Bronte sisters to be “Sex and the City” Victorian-style. It also has been dismissed by some reviewers as chick lit. It isn’t that either, especially because in the Middle East the book has drawn more male than female readers, Alsanea said.

At UIC’s College of Dentistry, she has become a minor celebrity, her literary achievement trumpeted on the school’s Web page.

“Here, I’m just getting the good side of it,” she said. “Back home, there is a lot more pressure. There is still a lot of controversy.”

Alsanea, who comes from a family of doctors and dentists, already has her degree in dentistry and is pursuing certification in endodontics, the specialization that deals with root canals. She plans to return to Saudi Arabia and open a practice next summer. She also plans to continue writing.

“I chose dentistry because I didn’t want to have to write for money,” she said. “I didn’t want to make a career out of writing. I wanted to have a steady job that would allow me to write as I pleased.”

Alsanea appears to have no trouble balancing two careers, said Chris Wenckus, head of the UIC endodontics program.

“We’ve made some accommodations, for instance when she has had to go on a book-signing tour, but she’s always been very careful that she doesn’t leave at a key time for classroom work,” he said.

“Girls of Riyadh” was effectively banned in Saudi Arabia; it couldn’t be legally sold or imported there. To avoid Saudi censors, Alsanea had the book published in Lebanon. As enthusiasm spread by word of mouth and the Internet, smuggled copies of the book traded under the counter for $500 a copy, Alsanea said.

The Saudi government eventually relented and allowed the book to be imported, but many bookstores still refuse to carry it.

Alsanea is a gifted storyteller. She has an eagle eye for the revealing detail, such as Saudi males’ penchant for traditional desert thobes (white robes) and head scarves _ but with Gucci or Givenchy labels.

The four women in “Girls of Riyadh” have been friends since their school days. As they pursue love in a society dominated by men, social convention and tribal tradition, they also spend a lot of time shopping and discussing makeup.

The book’s real value lies in the rare glimpse it gives Western readers into the normally sequestered precincts of Saudi Arabia’s “velvet society,” the class of affluent Saudis who glide from Riyadh to London to Chicago, floating on the surface of modernity but anchored to the desert mind-set.

She writes about the yearning of young Saudis to escape the constraints of the rigid tribal and religious strictures of their parents. At the same time, she is attuned to the profound sense of obedience and conformity to tradition that govern relations between men and women.

Alsanea grew up in the society she writes about, a society in which Islam suffuses everything, and ruinous scandal lurks around every corner.

“Even for people who are not religious, religion is part of everyday life,” said Alsanea as she sipped ice tea at a Starbucks on the near North Side. “When a girl decides to tweeze her eyebrows, she consults a sheikh to make sure that what she is doing is correct. It’s a kind of weakness. We are afraid to do anything on our own.”

The Kingdom of Saudi Arabia may be built on oil and Islam, but everyday life revolves around the Internet and mobile phone. That reality is woven throughout Alsanea’s book as romances bloom and wither in cyberspace, and young people in Riyadh shopping malls furtively exchange glances and phone numbers.

Alsanea knew from the time she was a teen that she wanted to be a writer. She began “Girls of Riyadh” when she was an 18-year-old student at a women’s college in Riyadh.

She said that an openness with her family and friends that is unusual by Saudi conventions enabled her to tackle subjects that most Saudis feel should not be aired in public.

“My family was very understanding,” she said. “I’m talking about a family that didn’t ask me what I was going to write about, didn’t argue with me about publishing it, didn’t try to stop me from publishing it under my own name.” Although Alsanea wrote the book for a Saudi audience with no expectation that it would ever be translated into English and sold in America, she hopes that Americans who read it will come to understand a dimension of Saudi life that transcends the stereotypes of bearded sheikhs and veiled women: “To see it as it is, even if it is not a perfect place,” she said.

___

A PEEK INTO WORLD OF ‘GIRLS’

The plot of “Girls of Riyadh” unfolds as a series of e-mails posted by a female narrator whose identity is ambiguous (“I am every one of my friends and my story is their story.”) Each installment is introduced with the narrator’s response to comments from her fictitious readers about how the plot is developing, interspersed with scraps of Arabic poetry and other quotations, advice from Muslim televangelists and the odd quote from Mark Twain or Eleanor Roosevelt.

Here is an excerpt:

To: [email protected]

From: “seerehwenfadha7et”

Date: September 17, 2004

Subject: The Migrating Bird

To those who have totally annoyed me by declaring that I do not represent the girls of Saudi Arabia, I say: How many times do I have to repeat myself? I am not writing anything incredible or bizarre or so weird that you people absolutely do not relate to it or can say it’s not true! Everything I say, the girls in my society know very well. …

Michelle discovered that the epidemic of contradictions in her country had gotten so out of control that it had even infected her parents. Her father, whom she regarded as a rare symbol of the freedom in Saudi Arabia, had (himself!) now smashed the pedestal she had put him on. …

Her father exploded … when he heard her suggest how much she liked her cousin Matti. …

What if Matti really did love her? She knew that was unlikely, but she couldn’t help but think: was she going to give him up for the sake of her family, as Faisal had let her go for the sake of his family?

___

(c) 2008, Chicago Tribune.

Visit the Chicago Tribune on the Internet at http://www.chicagotribune.com/

Distributed by McClatchy-Tribune Information Services. For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Metabolon and University of Texas Partner in Diabetes Research

Metabolon, a provider of metabolomics-driven biomarker discovery and analysis, has announced that it is collaborating with Ralph DeFronzo and colleagues at The University of Texas Health Science Center at San Antonio.

The partnership will help drive development of Metabolon’s pre-diabetes diagnostic products as well as provide valuable data for insulin resistance and diabetes-related research.

Metabolon will be analyzing samples from various studies conducted by Dr DeFronzo’s team to discover and validate biochemical biomarkers reflective of insulin resistance and beta cell dysfunction.

These biomarkers will be used to help further develop Metabolon’s diagnostic tests in the area of insulin resistance, and how this relates to risk of developing metabolic diseases such as diabetes.

John Ryals, CEO of Metabolon, said: “It is through collaborations like this one with Dr DeFronzo’s team that Metabolon will be able to offer a unique diagnostic test that can help physicians to identify asymptomatic, pre-diabetic patients years before they become diabetic.”

Meaghan Onofrey Named President of MBS/Vox

CommonHealth today announced the promotion of Meaghan Onofrey to president of MBS/Vox, the research consultancy unit of CommonHealth specializing in the analysis of naturally occurring healthcare interactions, including in-office physician-patient dialogue.

CommonHealth (www.commonhealth.com) is the world’s leading healthcare-communications network and a WPP (NASDAQ: WPPGY)(www.wpp.com) company.

Advancing from her previous role as general manager, Ms. Onofrey will oversee the management, operation and long-term planning for MBS/Vox, which includes innovating the group’s unique, reality-based research techniques for analyzing healthcare dialogue and driving strategy for pharmaceutical brands. Already in development are several new offerings, including a hospital-based methodology, and an initiative to address the question of how to drive medication adherence. Additionally, Ms. Onofrey will work with inter-company account teams to maximize client research and strategy offerings.

“In her five years at MBS/Vox, Meaghan has consistently exhibited outstanding leadership and creativity,” said Joe Gattuso, Chief Strategist for CommonHealth and former President of MBS/Vox. “She has played a significant role in many new business wins and in further strengthening our linguistic and marketing teams over the past year, making it our most successful year yet,” he added.

MBS/Vox, founded in 2000, was the first company to look into the exam room and assess physician-patient dialogue. This insight offered a radical shift from traditional market research because of the ability to see how physicians and patients actually talk about pharmaceutical brands and categories in real-life visits. The group has an extensive database of physician-patient interactions, and has published more than twenty-five articles documenting study results.

Ms. Onofrey joined MBS/Vox five years ago with extensive training in medical linguistics. During her five-year tenure, she has worked on more than eighty studies in a diverse assortment of therapeutic categories, including the first study to measure the impact of physician training on office dialogue. She has co-authored twenty publications and designed an array of communications-based tactical programs for her pharmaceutical clients. Ms. Onofrey holds a bachelor’s degree in linguistics and a master’s degree in sociolinguistics, both from Georgetown University.

CommonHealth comprises MBS/Vox, Altum, Carbon, CommonHealth London, CommonHealth Paris, Conectics, Earthborn, EvoLogue, Ferguson, HLS, Noesis, ProCom, Qi and Solara. The organization also maintains numerous partnerships both within and outside of the WPP network of companies.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=802446

 Contact: Beth Paulino or Kerianne McGuire CommonHealth (973) 352-1000  

SOURCE: MBS/Vox

BodyTel’s Blood Glucose Monitoring and Diabetes Management System, GlucoTel, Passes TNO Tests

JACKSONVILLE, Fla., July 23, 2008 (PRIME NEWSWIRE) — BodyTel Scientific Inc. (OTCBB:BDYT), a developer and manufacturer of wireless telemedical systems, announces today that the GlucoTel system has received certification from the Netherlands Organization for Applied Scientific Research TNO (“TNO”) by passing rigorous quality assurance tests. TNO is an independent group founded in 1932 that, among other things, thoroughly tests and inspects medical devices.

“The TNO approval offers consumers the reassurance that a product has been thoroughly tested and periodically monitored by an independent organization. TNO is known throughout Europe for their high standards and its tests are often more rigorous than the requirements for CE Marking,” stated, BodyTel CEO, Stefan Schraps. “Receiving the TNO approval is a testament to the accuracy and quality of the GlucoTel system.”

Dion van de Ven, CEO of TeleHealth Services, BodyTel’s distributor in the Benelux region, commented, “The TNO approval seal will assist us with the introduction of this telemedical solution within medical institutes, as well as assist our efforts in differentiating our product from our competitors. Also, there are already some insurance companies who are considering requiring the TNO certificate in order to have the costs reimbursed by them. Most important for the Benelux market is that the certification gives the quality-image that GlucoTel deserves.”

The GlucoTel system is a complete telemedical blood glucose monitoring and diabetes management system, supporting patients and healthcare professionals in the treatment and control of diabetes and other associated disorders. GlucoTel electronically measures the blood sugar level and then sends it automatically via Bluetooth to the patient’s cell phone. Measured values are automatically transmitted from the cell phone to BodyTel’s online database via mobile Internet connection and stored on a long-term basis in the patient’s secured profile. To facilitate better diabetes management, the patient and any authorized persons, e.g. healthcare professionals or other caregivers, can access the database ‘BodyTel Center’ at www.bodytel.com via the Internet at any time using a secure login.

The GlucoTel system is the first system of its kind that can provide real-time monitoring and management through its optional alarm functions. If defined by the caregiver, the BodyTel Center can create an alert message that can be sent to caregivers such as parents of a diabetic child, thereby informing them immediately of a potential out-of-range result or other unusual behavior like not performing any test within a predefined time frame. The versatility of the system provides all these tools, but use is completely optional and can be enabled or disabled based on patient, caregivers or healthcare professionals’ requirements preventing possible serious complications if action is taken without delay.

About BodyTel

BodyTel is a German-American telehealth company that specializes in telemedical monitoring and management systems for chronic diseases. The company combines its know-how in telecommunications, Internet and medical technology/diagnostics to create new products and services for the changing needs of global health. BodyTel products are designed not only to simplify home monitoring by patients, but also to ease the communication of ‘measured body values’ to healthcare professionals or other caregivers by bridging the gap between the patient and the caregivers instantaneously and in real-time. BodyTel’s products — GlucoTel, PressureTel and WeightTel — are each at different stages of development and approval processes.

Further information can be found at www.bodytel.com.

Forward-Looking Statements

Statements in this news release that are not historical are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,””plans,””anticipates,””believes,””intends,””estimates,””projects,””aims,””potential,””goal,””objective,””prospective,” and similar expressions, or that events or conditions “will,””would,””may,””can,””could” or “should” occur. Forward-looking statements in this news release include: The TNO approval seal will assist us with the introduction of this telemedical solution within medical institutes, as well as assist our efforts in differentiating our product from our competitors. It is important to note that the Company’s actual outcomes may differ materially from those statements contained in this press release. Factors which may delay or prevent these forward looking statements from being realized include, but are not limited to those concerning the timing of regulatory approval or commercialization of its products or the achievement of any other clinical, regulatory or product development milestones or other risk factors and matters set forth in the Company’s Annual Report on Form 10-KSB for the year ended February 28, 2007 and the Company’s periodic reports filed with the SEC. These reports are available on our investor relations website at www.bodytel.com and on the SEC’s website at http://www.sec.gov. BodyTel undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

This news release was distributed by PrimeNewswire, www.primenewswire.com

 CONTACT:  BodyTel Europe GmbH           Michaela Klinger           +49 (0)5621 96776 11           [email protected]            chain relations           Torsten Herrmann           06192/96 166 80           [email protected]            ZA Consulting Inc.           U.S. Investor Relations           David Zazoff           212-505-5976